Rhrtuefmero O
, O
we O
observed O
no O
correlation O
between O
the O
smoitac O
mutation O
rate O
and O
itusse O
proliferation O
capacity O
. O
 
The O
somatic O
maoutitn O
rates O
in O
in O
rdffeient O
tissues O
were O
aslo O
not O
correlated O
to O
the O
the O
the O
relative O
inter O
- O
tseius O
difcreenfe O
transcriptional O
levels O
of O
terhe O
genes O
( O
DMAHP O
, O
PMDK O
and O
59 O
) O
surrounding O
repeat O
. O
. O
 
A O
novel O
sinsesme O
mutation O
in O
eatpints O
from O
a O
lotasontabrmei B
retinoblastoma B
pigedree O
showing O
only O
mild O
epxrensios O
of O
the O
tumor B
phenotype O
. O
 
We O
have O
used O
lnigse O
strand O
conformation O
phlomyrpsiom O
analysis O
to O
study O
the O
the O
the O
27 O
exons O
of O
of O
RB1 O
egne O
in O
individuals O
from O
a O
family O
siownhg O
mild O
eepsxsrion O
iatrentmlsboao B
retinoblastoma B
ppeyotnhe O
. O
 
In O
this O
family O
affected O
laddviiunis O
developed O
unilateral B
tusmor I
tumors I
and O
, O
, O
as O
a O
rtsuel O
of O
linkage O
alasynis O
unaffected O
tutmaion O
carriers O
were O
slao O
identified O
within O
the O
pedigree O
. O
 
A O
gsnile O
band O
shift O
using O
SCSP O
was O
identified O
in O
in O
in O
xeon O
exon O
xeon O
exon O
21 O
which O
seurlted O
a O
a O
mssiense O
mutation O
converting O
cys O
- O
- O
> O
arg O
at O
nucleotide O
stpioion O
28 O
the O
. O
 
The O
mutation O
destroyed O
an O
NdeI O
restriction O
ynezme O
tise O
. O
 
Analsyis O
of O
of O
all O
almify O
rbmeems O
demonstrated O
that O
the O
the O
missense O
mutation O
mtuatoin O
mutation O
mtuatoin O
co O
- O
geeregatsd O
with O
with O
patients O
mtrous B
tumors B
or O
who O
, O
as O
a O
result O
lieknga O
analysis O
had O
been O
predicted O
to O
carry O
prengsdosipi O
. O
 
Thsee O
observations O
point O
to O
hnatoer O
eigron O
of O
of O
the O
the O
the O
RB1 O
gene O
gene O
where O
umtatnois O
only O
fydimo O
function O
and O
raise O
important O
questions O
for O
genetic O
counseling O
in O
families O
with O
these O
dsiitnvtice O
phentoypes O
. O
. O
 
Mrenatal B
Maternal B
disomy I
and O
Paerdr B
Prader B
- I
Willi I
mnrdysoe I
syndrome I
consistent O
with O
gamete O
completentamion O
in O
a O
csae O
of O
faimllai O
translocation O
( O
( O
3 O
; O
; O
15 O
) O
) O
p25 O
q11 O
. O
. O
2 O
 
Mtreaanl B
Maternal B
uapirnenatl I
uniparental I
omsdyi I
disomy I
( I
UPD I
) I
for I
emrshocoom I
chromosome I
15 I
is O
resopnislbe O
for O
an O
estimated O
30 O
% O
of O
of O
saces O
Rrpaed B
Prader B
- I
Iiwll I
Willi I
yrndomse I
syndrome I
( O
PWS B
) O
. O
 
We O
report O
on O
an O
snuuual O
easc O
of O
of O
matnlear B
maternal B
somidy I
disomy I
15 I
in O
PWS B
that O
is O
most O
consistent O
with O
with O
dajanect O
- O
1 O
segregation O
a O
ptneraal O
t O
( O
( O
3 O
; O
; O
15 O
15 O
) O
) O
p25 O
q11 O
. O
. O
2 O
simultaneous O
matenarl O
teioimc O
noodisitncujnn O
for O
chromosome O
 
The O
iatptne O
( O
( O
J O
. O
. O
. O
B O
) O
) O
, O
, O
, O
, O
a O
a O
17 O
- O
- O
yera O
old O
white O
male O
with O
with O
PWS B
was O
fuond O
to O
have O
47 O
chromosomes O
eupsryrmeuarn O
paletnar O
der O
15 O
15 O
consisting O
of O
of O
the O
the O
sohrt O
arm O
arm O
arm O
and O
and O
plorimax O
lnog O
chromosome O
chromosome O
dtslai O
3p O
 
The O
t O
( O
3 O
; O
15 O
) O
was O
eprsent O
in O
in O
the O
the O
bdeancla O
state O
aptneits O
father O
and O
a O
itsser O
. O
 
Fluorescent O
in O
in O
istu O
hybridization O
analysis O
detrnotsamed O
that O
that O
the O
the O
the O
the O
PWS B
PWS B
critical O
rogein O
iogren O
rogein O
iogren O
resided O
on O
on O
deravitvie O
cmrsmooohe O
3 O
and O
there O
was O
no O
deletion O
of O
of O
normal O
pria O
15s O
present O
J O
. O
 
B O
. O
 
Methylation O
analysis O
at O
exno O
aplha O
of O
of O
the O
the O
msall O
nuclear O
ribonucleoprotein O
- O
aotsciased O
polypeptide O
N O
( O
SNRPN O
) O
gene O
showed O
a O
pattern O
ciaractetisrhc O
only O
maternal O
chmoorsome O
15 O
in O
J O
. O
 
B O
. O
 
Lrtaneam B
Maternal B
disomy I
was O
confirmed O
by O
polymerase O
chain O
reaction O
inlaysas O
of O
licrostaemtile O
tapeers O
at O
the O
gamma O
- O
aminobutyric O
acid O
receptor O
beta3 O
sbunuit O
( O
GABRB3 O
) O
locus O
. O
 
A O
niece O
( O
( O
B O
B O
. O
. O
. O
) O
) O
with O
with O
45 O
moeochsomrs O
and O
the O
the O
derivative O
3 O
3 O
but O
without O
der O
15 O
aemotsdrnted O
a O
phenotype O
tosnistenc O
that O
reported O
for O
haulofnscifpiiency O
of O
daitsl O
p O
 
Raepainntul B
Uniparental B
oysmdi I
disomy I
tsaocisaed O
with O
lnbauanced O
seeggration O
of O
of O
non O
- O
Roonrstbniae O
translocations O
has O
has O
been O
been O
reported O
previously O
but O
not O
, O
, O
to O
our O
knowlgede O
observed O
in O
a O
case O
PWS B
. O
 
Forthuemrre O
, O
our O
findings O
are O
best O
interpreted O
as O
true O
gamete O
coeolemmntatnpi O
rseulitng O
in O
mtleaarn B
maternal B
UPD I
15 I
and O
PWS B
 
Arwcshtz B
Schwartz B
- I
- I
Maljep I
Jampel I
syndrome I
smdyrnoe I
syndrome I
smdyrnoe I
ypte I
type I
2 I
and O
Stuve B
Eiewnmnad I
Wiedemann I
: O
a O
acse O
for O
" O
lumping O
" O
. O
 
Recent O
studies O
demonstrated O
the O
the O
existence O
of O
of O
of O
a O
gnaelicetly O
distinct O
, O
, O
lausuly O
lethal O
rofm O
Achrtswz B
Schwartz B
- I
Japmel I
Jampel I
nymdrose I
syndrome I
( O
SJS B
SJS B
) O
myontoia B
myotonia B
and O
lkesteal B
skeletal B
yispsdala I
dysplasia I
which O
we O
claled O
type I
2 I
. O
 
This O
eisroddr O
is O
reminiscent O
of O
hnoraet O
rare O
condition O
, O
, O
, O
, O
the O
Stuve B
- I
Imwanedne I
Wiedemann I
syndrome I
( O
SWS B
) O
which O
comprises O
clmaaepmio B
campomelia B
at O
btrih O
with O
skeletal B
alspsdyia I
dysplasia I
ceotrnutsarc B
contractures B
and O
leyar B
early B
adhte I
death I
. O
 
To O
tset O
for O
possbiel O
nosologic O
identity O
between O
these O
disorders O
, O
, O
we O
reveweid O
the O
the O
letriature O
and O
and O
abiotned O
a O
follow O
- O
up O
of O
only O
two O
surviving O
patients O
one O
with O
with O
SJS B
ypte I
type I
2 I
at O
at O
age O
age O
10 O
yeras O
yraes O
yeras O
yraes O
naorhet O
SWS B
7 O
. O
 
Patients O
reported O
as O
having O
either O
oannetal O
SJS B
or O
SWS B
presented O
a O
a O
a O
combination O
of O
severe O
, O
, O
, O
, O
prneatal O
- O
onset O
leuormusrnuca B
neuromuscular B
rdiosred I
disorder I
( O
with O
with O
cgnoenitla B
congenital B
joint I
contractures I
respiratory O
and O
and O
efednig O
siflciuftied O
tendency O
to O
etraryehpmih B
hyperthermia B
fqnrueet O
dhate O
in O
infancy O
) O
distinct O
acmpomcile B
campomelic B
- I
myeahpsteal I
metaphyseal I
skeletal I
diaslpasy I
dysplasia I
. O
 
The O
similarity O
of O
the O
cilnicla O
and O
radpgohairic O
ngndifis O
is O
so O
extensive O
that O
these O
disorders O
ppaear O
to O
be O
a O
single O
entity O
. O
 
The O
looflw O
- O
up O
observation O
of O
of O
of O
an O
identical O
and O
unique O
taetprn O
sorgserpive O
eobn B
bone B
alspdyais I
dysplasia I
in O
in O
the O
the O
two O
patients O
( O
one O
one O
with O
with O
SJS B
eytp I
type I
2 I
, O
SWS B
) O
surviving O
bdynoe O
infancy O
adds O
to O
deivence O
oavfr O
tnedtiiy O
. O
 
The O
hypothesis O
that O
SWS B
and O
SJS B
ptye I
type I
2 I
are O
the O
same O
disorder O
should O
be O
testbale O
by O
aolecmlur O
tedhoms O
. O
. O
 
A O
mouse O
model O
of O
severe O
von B
Ewlindralb I
Willebrand I
deseais I
disease I
: O
fedtces O
in O
htmoseasis O
and O
thrombosis B
. O
 
von B
von B
Rbnleiwald I
Lnealdrwib I
Willebrand I
Rbnleiwald I
Lnealdrwib I
Willebrand I
focrta I
factor I
( I
vWf I
) I
cefiiyencd I
deficiency I
caeuss O
severe O
esieasd I
disease I
in O
humans O
. O
 
We O
generated O
a O
muose O
model O
for O
this O
diaesse O
by O
usnig O
gene O
targeting O
. O
 
vWf B
- I
ienfecidt I
deficient I
mice O
aaeppred O
normal O
at O
birth O
; O
they O
were O
viable O
and O
ieftrle O
. O
 
Neither O
vWf O
vWf O
nor O
peopoylepptidr O
( O
von B
Ealrwnilbd I
Willebrand I
ainnget O
II O
) O
were O
dleectabte O
in O
plasma O
, O
, O
platelets O
or O
endothelial O
cells O
of O
the O
homozygous O
aunmtt O
mice O
. O
 
The O
mutant O
mice O
edhebitix O
tedecfs O
in O
in O
hemostasis O
with O
a O
highly O
prolonged O
ilebdeng O
bleeding O
ilebdeng O
bleeding O
time O
and O
spontaneous O
evtsen O
apprlximatoey O
10 O
% O
of O
neonates O
. O
 
As O
in O
in O
the O
the O
the O
hunam O
aesidse O
, O
frotca O
VIII O
lveel O
these O
mice O
was O
reduced O
strongly O
as O
a O
seurlt O
of O
of O
lack O
irotpcteon O
provided O
by O
vWf O
. O
 
Defective O
ihosmtorbs B
thrombosis B
in O
in O
in O
muantt O
mcie O
was O
also O
evident O
an O
ivvo O
model O
of O
aalrvsuc B
vascular B
injury I
. O
 
In O
this O
model O
, O
the O
the O
xdteriirozee O
mtseneyre O
was O
was O
superfused O
with O
freric O
chloride O
and O
accumulation O
of O
nlutfesceroly O
labeled O
platelets O
observed O
by O
intravital O
mircosocpy O
. O
 
We O
conclude O
that O
these O
mice O
very O
very O
coslely O
miimc O
seveer O
hunam O
von B
Wibeldranl I
Willebrand I
eaissde I
disease I
and O
and O
will O
be O
uesluf O
for O
investigating O
the O
role O
of O
vWf O
in O
in O
normal O
physiology O
disease O
mledos O
. O
. O
 
Roal O
contraceptives O
and O
the O
rsik O
of O
teradihrey B
hereditary B
ovarian I
crncae I
cancer I
. O
 
Heyerdtair B
Hereditary B
Ovarian I
Ecacnr I
Cancer I
Clinical O
Sutdy O
Group O
. O
 
BACKGROUND O
Women O
with O
outmtians O
in O
eiehtr O
the O
the O
BRCA1 O
or O
BRCA2 O
gene O
have O
a O
ihgh O
lifetime O
sirk O
of O
oanvira B
ovarian B
cancer I
. O
 
Oarl O
toneracvptices O
protect O
protect O
against O
against O
orvaina B
ovarian B
acecnr I
ecncra I
cancer I
acecnr I
ecncra I
cancer I
in O
general O
, O
but O
it O
is O
not O
nkown O
whether O
they O
laso O
hereditary B
smorf I
forms I
of I
ovarian I
. O
 
METHODS O
We O
enrldleo O
207 O
women O
with O
hdretiyare B
hereditary B
ovarian I
crecan I
cancer I
and O
161 O
of O
their O
sisters O
as O
lsntroco O
in O
a O
cesa O
- O
ocnortl O
study O
. O
 
All O
the O
patients O
cadirer O
a O
pathogenic O
nttauiom O
in O
eihetr O
BRCA1 O
( O
( O
179 O
women O
women O
) O
) O
or O
BCRA2 O
28 O
. O
 
The O
control O
wemon O
were O
elnorled O
regardless O
of O
whether O
or O
not O
they O
had O
eiehrt O
mutation O
. O
 
Tifelime O
srhtoiies O
of O
of O
oral O
- O
vcntracepoite O
use O
were O
were O
obtained O
by O
by O
ietvrniew O
or O
written O
questionnaire O
and O
and O
and O
compared O
between O
patients O
colortn O
mowen O
, O
after O
adjustment O
for O
year O
birth O
parity O
. O
 
REUSLTS O
The O
jdtusaed O
odds O
iatro O
for O
ovarian B
arecnc I
cancer I
associated O
with O
any O
past O
use O
of O
oral O
coattvceprines O
was O
0 O
. O
 
5 O
( O
95 O
percent O
cnofidecne O
netirval O
, O
0 O
0 O
. O
. O
. O
3 O
to O
8 O
) O
 
The O
rsik O
kisr O
rsik O
kisr O
decreased O
with O
with O
encrnasiig O
duration O
of O
use O
use O
( O
P O
for O
for O
ternd O
, O
< O
0 O
. O
. O
001 O
) O
; O
six O
or O
more O
yaers O
was O
associated O
a O
60 O
perenct O
reduction O
in O
 
Oral O
- O
cetnracvptioe O
use O
tortecped O
against O
aviroan B
ovarian B
cancer I
both O
for O
for O
caeirrrs O
carriers O
caeirrrs O
carriers O
of O
of O
the O
the O
BRCA1 O
mutation O
mutation O
( O
( O
odds O
odds O
ratio O
ratio O
, O
, O
, O
, O
0 O
0 O
0 O
0 O
0 O
. O
. O
. O
. O
. O
. O
. O
5 O
; O
; O
95 O
95 O
ptcrene O
enrcept O
ptcrene O
enrcept O
confidence O
eonficdnce O
confidence O
eonficdnce O
vnteairl O
interval O
vnteairl O
interval O
3 O
to O
to O
9 O
) O
) O
and O
BRAC2 O
4 O
2 O
1 O
1 O
 
CONCLUSIONS O
Arol O
- O
contraceptive O
use O
may O
reduce O
the O
the O
rsik O
of O
aivraon B
ovarian B
cancer I
in O
in O
womne O
with O
pghtoaenic O
mutations O
BRCA1 O
or O
BRCA2 O
gene O
 
A O
Japanese O
flaimy O
with O
with O
odrnedlekphrystauooy B
adrenoleukodystrophy B
a O
a O
codno O
291 O
deoeitln O
: O
clinical O
, O
, O
, O
boichemiacl O
pathological O
and O
genetic O
report O
. O
 
We O
report O
a O
a O
Japanese O
imafly O
with O
with O
rheouodrayedpstnoylk B
adrenoleukodystrophy B
( O
( O
ALD B
ALD B
) O
) O
terhe O
base O
apir O
deletion O
delGAG O
291 O
in O
the O
nege O
. O
 
A O
ivraety O
of O
phenotypes O
were O
observed O
within O
this O
yafilm O
. O
 
While O
the O
prdabno O
( O
( O
( O
patient O
peniatt O
patient O
peniatt O
patient O
peniatt O
1 O
) O
) O
) O
was O
ciassifeld O
as O
having O
a O
a O
rare O
anteredmiite O
type O
tpye O
type O
tpye O
of O
adult O
cerebral O
and O
and O
cerebello O
- O
brain O
stem O
froms O
, O
his O
younger O
brother O
2 O
nwphee O
3 O
had O
childhood O
ALD B
. O
 
Hnoraet O
nephew O
( O
patient O
patient O
4 O
) O
of O
1 O
was O
slascified O
as O
having O
an O
adelescnot O
form O
. O
 
The O
tau O
level O
in O
in O
the O
cerebrospinal O
fulid O
( O
( O
CSF O
) O
) O
nitaept O
1 O
was O
as O
as O
high O
that O
of O
pntaeits O
with O
Ahmlsezrie B
Alzheimers B
sidesae I
disease I
AD B
. O
 
His O
biarn O
brain O
biarn O
brain O
mngeatic O
cesonaner O
iamge O
( O
( O
MRI O
) O
) O
showed O
abnmearitsloi B
abnormalities B
in I
the I
bialetrla I
bilateral I
cerebellar I
merpsieehhs I
hemispheres I
and O
and O
stem O
, O
, O
but O
not O
in O
the O
the O
cerebarl O
cerebral O
cerebarl O
cerebral O
white O
martte O
where O
marked O
reductions O
of O
blood O
flow O
oxygen O
metlbosiam O
were O
clearly O
demonstrated O
by O
positron O
meissoin O
tomography O
PET O
. O
 
In O
patients O
2 O
and O
3 O
, O
, O
the O
the O
the O
ostapuy O
fiindngs O
dinfings O
fiindngs O
dinfings O
showed O
maseisv O
amiyitonldeen B
demyelination B
of I
the I
larerebc I
cerebral I
ithwe I
white I
teatmr I
matter I
with O
with O
sparing O
of O
of O
U O
- O
brfeis O
compatible O
childhood O
ALD B
. O
 
Oceil O
and O
and O
erucic O
acids O
( O
Lornozes O
Oil O
) O
were O
mdnisiatered O
to O
patients O
1 O
4 O
, O
but O
sufficient O
tffeneivscese O
was O
not O
obtained O
. O
 
The O
findings O
in O
this O
family O
suggest O
that O
dleGA2g91 O
is O
prat O
of O
of O
the O
cause O
Jspaenae O
ALD B
with O
pyenotiphc O
variations O
. O
 
Voeromer O
, O
, O
, O
although O
the O
the O
the O
the O
scale O
of O
of O
of O
sduty O
is O
is O
is O
dimietl O
there O
a O
lissobiptiy O
that O
that O
PET O
can O
tetced O
an O
sioisnudi B
insidious B
oslien I
lesion I
which O
utdnaecteble O
by O
computed O
tomogram O
( O
CT O
) O
or O
MRI O
analysis O
and O
erghhi O
level O
tau O
reflects O
process O
neuronal B
anoeetrdgien I
degeneration I
in O
ALD B
. O
 
Loroezns O
Oil O
should O
be O
given O
in O
the O
eraly O
stage O
. O
. O
 
Nonsense O
umiatton O
in O
exon O
4 O
of O
of O
human O
complement O
C9 O
egne O
is O
the O
amjor O
csuae O
Japanese O
cmomlnpeet B
complement B
C9 I
dicienfcey I
deficiency I
. O
 
Deficiency B
of I
of I
the I
ntihn I
ninth I
tomonenpc I
component I
hnuma I
human I
oemlpemcnt I
complement I
( O
C9 O
) O
is O
is O
the O
most O
common O
emmptolcne B
complement B
deficiency I
in O
in O
Japan O
but O
arre O
other O
coutrnies O
. O
 
We O
studied O
the O
molecular O
bsais O
of O
C9 B
C9 B
dfeiceciny I
deficiency I
in O
uofr O
Aapjnsee O
- I
efdicenit I
deficient I
patients O
who O
had O
suffered O
from O
emnanioccocgl B
meningococcal B
genmntiisi I
meningitis I
. O
 
Idcert O
sequencing O
of O
amplified O
C9 O
cDNA O
and O
DNA O
revealed O
a O
nonsense O
sutttiiubson O
( O
CGA O
- O
- O
> O
TGA O
) O
at O
docon O
95 O
in O
in O
xeon O
4 O
the O
four O
C9 B
- I
eeindfcit I
deficient I
indiuidvlas O
. O
 
An O
aleell O
- O
fcecisip O
palmyerose O
chain O
reaction O
system O
designed O
to O
ettdce O
ecvsulixely O
only O
one O
of O
of O
the O
the O
the O
the O
normal O
and O
and O
nttamu O
alleles O
eadicntid O
that O
that O
all O
uofr O
patients O
were O
were O
homozygous O
for O
mutation O
in O
xeon O
4 O
parents O
patient O
2 O
heterozygous O
. O
 
The O
mmcoon O
mutation O
at O
cdoon O
95 O
in O
exon O
4 O
higmt O
be O
responsible O
for O
most O
Japanese O
C9 B
neccfiiedy I
deficiency I
. O
. O
 
BRCA1 O
reieqrud O
for O
transcription O
- O
coupled O
repair O
of O
oidiatxve O
DNA O
damage O
. O
 
The O
bersta B
breast B
and I
aovrain I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
encodes O
a O
znic O
enigfr O
protein O
of O
unknown O
function O
. O
 
Association O
of O
of O
the O
the O
the O
the O
BRCA1 O
RBCA1 O
BRCA1 O
RBCA1 O
protein O
nroietp O
protein O
nroietp O
protein O
nroietp O
with O
with O
DNA O
DNA O
DNA O
repair O
reapir O
repair O
reapir O
Ra5d1 O
and O
and O
ahcgnes O
in O
in O
phosphorylation O
cellular O
localiaztion O
after O
exposure O
to O
- O
dagamign O
agents O
are O
consistent O
a O
eolr O
for O
. O
 
Ehre O
, O
, O
it O
is O
hsown O
that O
mouse O
obmryenic O
etsm O
clels O
feiicdent B
deficient B
in I
AC1Br I
BRCA1 I
are O
are O
defective O
in O
the O
ability O
to O
to O
carry O
out O
transcription O
- O
coupled O
repair O
of O
oxidative O
DNA O
damage O
and O
and O
hypersensitive O
ionizing O
radiation O
oydrhgne O
pirexode O
. O
 
Htese O
seurlts O
suggest O
that O
BRAC1 O
participates O
, O
, O
directly O
or O
indirectly O
in O
transcription O
- O
coupled O
piraer O
of O
oxidative O
DNA O
damage O
. O
. O
 
Uitncatron O
mutations O
in O
in O
the O
transactivation O
ieorgn O
of O
PAX6 O
result O
dominant O
- O
negative O
attmnus O
. O
 
PXA6 O
is O
a O
a O
transcription O
factor O
with O
two O
DNA O
- O
- O
- O
- O
ibnding O
anmdios O
( O
( O
paired O
box O
and O
and O
homeobox O
) O
) O
riolpne O
serine O
threonine O
PST O
rich O
itansactivatron O
domain O
. O
 
PAX6 O
regulates O
eye O
lveedonmept O
in O
animals O
rgnagni O
from O
jellyfish O
to O
to O
Drosophila O
uamhns O
. O
 
Heterozygous O
mutations O
in O
in O
the O
human O
PXA6 O
gene O
uerslt O
various O
phenotypes O
, O
, O
, O
, O
includign O
aniridia B
Eteprs B
Peters B
anomaly I
asamutool B
autosomal B
dominant I
akerstiit I
keratitis I
and O
familial B
vaoefl I
foveal I
lyidaassp I
dysplasia I
. O
 
It O
is O
is O
beleevid O
that O
the O
mutdeta O
allele O
of O
PAX6 O
produces O
an O
ctainive O
protein O
and O
nrdaiiia B
aniridia B
caused O
due O
to O
genetic O
hnslocapuifiifency O
. O
 
However O
, O
several O
truntaoicn O
mutations O
have O
have O
been O
found O
to O
occur O
in O
in O
in O
the O
the O
the O
C O
- O
- O
terminal O
ahlf O
of O
of O
PAX6 O
piteants O
with O
Raanidii B
Aniridia B
resulting O
mtatnu O
portiens O
that O
retain O
DNA O
bindnig O
dnmiaos O
but O
lost O
most O
aovnsactiattirn O
domain O
. O
 
It O
is O
not O
clear O
whether O
such O
mutants O
mutants O
really O
behave O
as O
as O
olss O
- O
- O
of O
ftniucon O
pciderted O
by O
hapfnincilfisueocy O
. O
 
Contrary O
to O
this O
theory O
, O
our O
data O
showed O
that O
these O
mutants O
are O
are O
aodinmnt O
- O
- O
negative O
in O
transient O
toaisftcenrn O
assays O
when O
they O
coeepesxsrd O
with O
wild O
type O
PAX6 O
. O
 
We O
found O
that O
the O
the O
dominant O
- O
tvganiee O
effects O
reltsu O
from O
encdnhea O
DNA O
binding O
batliiy O
of O
these O
mutants O
. O
 
Kenitic O
studies O
of O
binding O
nindgbi O
binding O
nindgbi O
and O
dissociation O
revealed O
that O
various O
various O
tirncatuon O
mutants O
have O
3 O
- O
- O
- O
- O
5 O
fold O
higher O
affinity O
to O
DNA O
istes O
when O
compared O
with O
the O
wild O
type O
XAP6 O
. O
 
Tehse O
results O
provide O
a O
new O
insight O
into O
the O
orle O
of O
mutant O
PAX6 O
in O
icusang O
dniariia B
aniridia B
. O
. O
 
Reversal O
of O
severe O
pyhretpohric B
hypertrophic B
taomcioydharpy I
cardiomyopathy I
and O
excellent O
ceoropsyihoulgnc O
oumctoe O
in O
very B
- I
- I
- I
long I
ahinc I
chain I
acyl I
oneczyme I
coenzyme I
A I
ryesdhgeenaod I
dehydrogenase I
nccieieydf I
deficiency I
. O
 
Ryve B
Very B
- I
- I
- I
lngo I
long I
aihcn I
chain I
acyl I
zcmnyoee I
coenzyme I
A I
ohaynregdedse I
dehydrogenase I
( I
ACVLD I
VLCAD I
) I
cefyicnedi I
deficiency I
is O
a O
disorder O
of O
of O
fttay O
acid O
btea O
oxdtaiion O
that O
reportedly O
has O
ihgh O
rates O
morbidity O
and O
mortality O
. O
 
We O
deicrebs O
the O
cutoome O
of O
of O
a O
5 O
5 O
- O
- O
yera O
old O
girl O
with O
with O
VLCAD B
deficiency I
who O
was O
first O
seen O
at O
mtnhos O
age O
sereev O
hypertrophic B
ocmaaohripdtyy I
cardiomyopathy I
, O
, O
, O
eyoltmhpgaae B
hepatomegaly B
aaneohelppcthy B
encephalopathy B
and O
oytonihpa B
hypotonia B
. O
 
Mhicoebical O
studies O
indicated O
LCVDA B
VLCAD B
deficiency I
sauecd O
by O
a O
stable O
yet O
inactive O
enzyme O
. O
 
Molecular O
tencgie O
ansylais O
of O
her O
VLCAD O
nege O
revealed O
a O
a O
723t1C O
( O
F854L O
) O
missense O
mutation O
mutation O
and O
1668 O
ACAG O
1669 O
splice O
site O
. O
 
Fater O
initial O
treatment O
with O
with O
intravenous O
glucose O
and O
and O
and O
carnitine O
carnitine O
, O
the O
patient O
has O
thrived O
on O
a O
low O
- O
- O
fat O
diet O
sueplnepetmd O
medium O
nhaic O
triglyceride O
oil O
aaoievncd O
of O
fnstaig O
. O
 
Her O
ventricular O
hypertrophy O
rsvoleed O
sigflnicanyit O
over O
1 O
reay O
, O
, O
and O
cognitively O
she O
is O
in O
the O
sopireur O
range O
for O
age O
. O
 
Clinical O
recingotoin O
of O
of O
of O
CALVD B
VLCAD B
ecciniedfy I
deficiency I
is O
is O
important O
because O
it O
one O
the O
few O
directly O
tlearabte O
causes O
cardiomyopathy B
in O
cliherdn O
. O
. O
 
Cloning O
of O
of O
a O
eovnl O
member O
the O
low O
- O
detsyni O
lipoprotein O
receptor O
fylima O
. O
 
A O
gene O
encoding O
a O
novel O
transmembrane O
protein O
was O
iednfitied O
by O
DNA O
eequcnes O
analysis O
within O
the O
insulin B
- I
edtpdeenn I
dependent I
aiesedtb I
diabetes I
mileutls I
mellitus I
( O
IDDM B
) O
locus O
ID4Md O
on O
cmrohosome O
11q13 O
. O
 
Baesd O
on O
its O
chromosomal O
position O
, O
this O
gene O
is O
a O
danciadte O
for O
conferring O
susceitibyiptl O
to O
itabeesd B
diabetes B
. O
 
The O
gene O
, O
, O
termed O
low O
low O
- O
- O
density O
density O
lepiorotipn O
oipoeiltprn O
lepiorotipn O
oipoeiltprn O
rotepcer O
receptor O
rotepcer O
receptor O
related O
ortpein O
protein O
ortpein O
protein O
5 O
( O
( O
RLP5 O
) O
) O
encodes O
a O
of O
of O
6115 O
nmiao O
acids O
that O
contains O
conserved O
modules O
which O
are O
characteristic O
the O
LDL O
family O
. O
 
These O
modules O
include O
a O
a O
a O
putative O
signal O
peptide O
for O
protein O
rxeopt O
, O
, O
, O
, O
uofr O
epidermal O
torwgh O
tafcor O
( O
( O
EGF O
) O
) O
repeats O
repeats O
with O
associated O
spacer O
domains O
three O
LDL O
- O
eecrtpor O
LDLR O
gisnle O
transmembrane O
spanning O
domain O
dniamo O
domain O
dniamo O
and O
cytoplasmic O
. O
 
The O
ecdoned O
protein O
has O
a O
a O
unique O
organization O
of O
of O
EGF O
and O
RDLL O
LDLR O
RDLL O
LDLR O
rapeste O
; O
therefore O
, O
RLP5 O
likely O
represents O
new O
category O
the O
falmiy O
. O
 
Both O
human O
and O
and O
mouse O
LRP5 O
cANDs O
have O
been O
oselatid O
the O
encoded O
mature O
prntoies O
are O
95 O
% O
iedntcial O
, O
indicating O
a O
high O
dgeree O
of O
evolutionary O
conservation O
. O
. O
 
The O
APC B
tarisnva O
I1307K O
and O
71e13Q O
are O
asosciated O
with O
with O
crlooceatl B
colorectal B
ormtsu I
tumors I
, O
but O
not O
always O
a O
family O
history O
. O
 
Classical O
lflimiaa B
familial B
aoudtnmaoes I
adenomatous I
polyposis I
( O
FAP B
) O
is O
a O
high O
- O
neeptrance O
loaostuam B
autosomal B
odnimnat I
dominant I
disease I
that O
that O
rpeeisposds O
to O
nuhderds O
or O
htnusaods O
of O
ltroeccaol B
colorectal B
adenomas I
and I
ncmcoaiar I
carcinoma I
and O
results O
from O
truncating O
tuoatimns O
in O
the O
APC B
gene O
. O
 
A O
variant O
of O
of O
FAP B
is O
ataenutted B
attenuated B
odemaauonts I
adenomatous I
oosyilpsp I
polyposis I
coli I
, O
which O
ertulss O
from O
regm O
- O
nile O
nutasiomt O
in O
the O
the O
5 O
and O
3 O
regions O
APC B
gene O
. O
 
Aetenutatd B
Attenuated B
aadnootumes I
adenomatous I
ysplposio I
polyposis I
coli I
pttianes O
have O
" O
multiple O
" O
colorectal B
mdeaaons I
adenomas I
( O
tyipyallc O
fewer O
than O
100 O
) O
wtuhoti O
the O
florid O
phenotype O
of O
classical O
FAP B
. O
 
Another O
gorup O
of O
patients O
with O
multiple O
oaanmdes B
adenomas B
has O
no O
mtoauitns O
in O
in O
the O
the O
APC B
gene O
, O
, O
, O
and O
their O
yhonetppe O
brolabpy O
results O
from O
variatoin O
at O
a O
locus O
or O
loic O
elsewhere O
genome O
. O
 
Recently O
, O
, O
, O
, O
however O
a O
missense O
vaitanr O
of O
of O
APC B
( O
37i01K O
) O
was O
described O
that O
rofnecs O
an O
increased O
risk O
craooetcll B
colorectal B
suotrm I
tumors I
including O
elltipum O
adenomas B
in O
Ashkenazim O
. O
 
We O
have O
eiudtsd O
a O
set O
of O
of O
164 O
patients O
with O
multiple O
oclaorcetl B
colorectal B
dmeaanos I
adenomas I
and I
/ I
or I
oarmccani I
carcinoma I
and O
ylanazed O
oodncs O
6213 O
- O
- O
1377 O
( O
exon O
15G O
) O
the O
APC B
gene O
for O
germ O
lnie O
variants O
. O
 
Three O
pitaents O
with O
the O
I1307K O
allele O
were O
detectde O
, O
each O
of O
Ashkenazi O
eesndct O
. O
 
Four O
patients O
had O
had O
a O
grem O
- O
nile O
E1317Q O
missense O
variant O
of O
of O
of O
APC O
that O
was O
not O
nrseept O
in O
oostrcln O
; O
one O
these O
dniividsaul O
an O
unusually O
large O
nurbme O
eiatmlpsatc B
metaplastic B
posypl I
polyps I
of I
the I
uocorlemct I
colorectum I
. O
 
There O
is O
incraesing O
evidncee O
that O
that O
there O
exist O
germ O
- O
line O
ivraants O
of O
of O
of O
the O
the O
the O
the O
APC B
gene O
predispose O
to O
development O
mlptilue O
oclerltoac B
colorectal B
oclerltoac B
colorectal B
mansoade I
adenomas I
and I
irncmcoaa I
carcinoma I
, O
, O
but O
oituwht O
irolfd O
ehpnotpye O
classical O
FAP B
and O
possibly O
with O
iapontmrce O
for O
aeccnr I
cancer I
risk O
in O
general O
population O
. O
. O
 
Genomic O
structure O
of O
the O
hmuan O
cgetonanil B
congenital B
chloride I
rharaied I
diarrhea I
( O
CLD B
) O
nege O
. O
 
Gnaecointl B
Congenital B
chloride I
eiahadrr I
diarrhea I
( O
CLD B
) O
is O
caused O
by O
mutations O
in O
a O
gene O
which O
necedos O
an O
intestinal O
anino O
srpntatroer O
. O
 
We O
rrpeot O
here O
the O
the O
complete O
genomic O
organization O
of O
human O
CLD B
gene O
which O
sapns O
approximately O
39kb O
, O
and O
comispres O
21 O
enoxs O
. O
 
All O
exon O
/ O
/ O
otnrin O
boundaries O
conform O
to O
the O
GT O
AG O
lure O
. O
 
An O
yaalnsis O
of O
the O
putative O
putative O
promoter O
region O
sequence O
shows O
a O
TATA O
box O
and O
predtics O
multiple O
transcription O
otcafr O
binding O
sites O
. O
 
The O
necomig O
genomic O
necomig O
genomic O
structure O
was O
determined O
using O
DNA O
DNA O
from O
from O
levares O
sources O
iuclnnidg O
multiple O
large O
- O
insert O
bliaries O
and O
and O
Finnish O
CLD B
patneist O
controls O
. O
 
Eoxn O
- O
specific O
primres O
developed O
in O
this O
study O
will O
facilitate O
motaitun O
screening O
dtisues O
of O
patients O
with O
the O
disease O
. O
 
Genomic O
siqneuceng O
of O
of O
of O
a O
a O
BAC O
colne O
H O
_ O
RG364P16 O
elveared O
the O
the O
the O
presence O
another O
, O
, O
, O
higlhy O
homologous O
gene O
egne O
gene O
egne O
gene O
egne O
3 O
CLD B
with O
similar O
genomic O
structure O
recently O
identified O
as O
Dneprde B
Pendred B
rynseodm I
syndrome I
( O
PDS B
) O
. O
. O
 
The O
A7CI103pK O
allele O
and O
ncacer B
cancer B
risk O
in O
a O
community O
- O
besad O
sutdy O
of O
Ashkenazi O
Jews O
. O
 
Mutations O
in O
APC O
are O
classically O
associated O
with O
lamfaiil B
familial B
smenoautoad I
adenomatous I
yoislpsop I
polyposis I
( O
( O
FAP B
) O
) O
, O
, O
, O
a O
hhigly O
penetrant O
lustomaoa B
autosomal B
domanint I
dominant I
disorder I
crarahetcized O
by O
multiple O
innesttial O
poyslp B
polyps B
and O
without O
surgical O
intervention O
the O
develepnomt O
of O
colorectal B
cancer I
CRC B
. O
 
APC B
is O
a O
tumour O
- O
soeprpssur O
gene O
, O
and O
somatic O
olss O
occurs O
in O
tomurus B
tumours B
. O
 
The O
rigmlene O
T O
- O
- O
- O
to O
to O
to O
A O
transversion O
reoisnlpbse O
for O
the O
the O
APC O
I1307K O
allele O
convrtes O
wild O
tpye O
sequence O
a O
homopolymer O
tract O
( O
A8 O
) O
that O
is O
ginyteeallc O
ultsabne O
and O
prone O
somatic O
mntutioa O
. O
 
The O
3170iK O
eallle O
was O
found O
in O
6 O
. O
 
1 O
% O
of O
of O
of O
enscleuted O
Ashkenazi O
Jews O
and O
higerh O
proportions O
Ashkenazim O
with O
yamlif O
or O
personal O
eishorits O
CRC B
( O
ref O
. O
. O
2 O
) O
 
To O
evaluate O
the O
role O
of O
7310iK O
in O
in O
nccaer B
cancer B
, O
, O
we O
genotyped O
5 O
081 O
Aakhenszi O
volunteers O
a O
omcmunity O
vursye O
. O
 
Rsik O
of O
developing O
cotlcreaol B
colorectal B
, I
artbes I
breast I
and I
other I
cnceras I
cancers I
were O
compared O
between O
gyonteped O
I1k370 O
carriers O
carriers O
and O
and O
non O
- O
- O
their O
frist O
degree O
relatives O
. O
 
Sperm O
DNA O
iyalnsas O
in O
in O
a O
Reicihedrf B
Friedreich B
xtaaia I
ataxia I
ptitumareon O
carrrie O
suggests O
both O
meiotic O
and O
titomic O
expansion O
the O
FRDA B
gene O
. O
 
Friedreich B
xiataa I
ataxia I
is O
usually O
caused O
by O
an O
axponsien O
of O
of O
a O
GAA O
ttirulceonide O
repeat O
in O
intorn O
1 O
the O
DFRA B
FRDA B
egne O
. O
 
Occasionally O
, O
a O
a O
fully O
expanded O
allele O
has O
been O
fuond O
to O
arise O
from O
moeputatnri O
of O
100 O
or O
less O
irtplet O
repates O
. O
 
We O
have O
examined O
the O
srepm O
DNA O
of O
a O
rpemoiattun O
carrier O
. O
 
This O
mans O
leucocyte O
DNA O
ohewsd O
one O
one O
norlma O
allele O
allele O
and O
of O
apxitprmaoely O
100 O
repeats O
. O
 
His O
srepm O
showed O
an O
expanded O
allele O
in O
a O
a O
tight O
rnage O
centering O
on O
size O
of O
rppaoxlmatyie O
320 O
trinucleotide O
rsepate O
. O
 
His O
affeectd O
son O
has O
repeat O
sizes O
of O
1040 O
and O
540 O
. O
 
These O
tada O
suggest O
that O
sxpaoeinn O
expansion O
sxpaoeinn O
expansion O
occurs O
in O
two O
stages O
, O
the O
first O
during O
meiosis O
wellofod O
by O
a O
second O
ictotmi O
. O
 
We O
also O
shwo O
that O
in O
all O
informative O
carrier O
carrier O
fethra O
to O
affected O
child O
transmissions O
, O
, O
with O
the O
the O
the O
natobel O
exception O
of O
uremnoatitp O
expansion O
size O
decsearse O
. O
. O
 
The O
R496H O
mitauton O
of O
arslylufatase O
A O
does O
not O
cause O
metachromatic B
doyholkstperuy I
leukodystrophy I
. O
 
Ieydeicnfc B
Deficiency B
of I
saulyrafltsae I
arylsulfatase I
A I
( O
( O
ARSA O
) O
) O
enzyme O
tciivtay O
causes O
ochrmaamettic B
metachromatic B
lhksudeooptryy I
leukodystrophy I
MLD B
. O
 
A O
number O
of O
ARSA O
gene O
matuitons O
olsnrpsibee O
for O
MLD B
have O
been O
dtendifiei O
. O
 
Recently O
, O
, O
the O
H496R O
mtaution O
of O
of O
ARSA O
was O
proposed O
to O
be O
a O
cause O
MLD B
( O
Igarhda O
et O
al O
. O
. O
9917 O
) O
 
We O
have O
invegtistaed O
the O
94r6H O
untatiom O
nuttaiom O
untatiom O
nuttaiom O
and O
found O
this O
at O
a O
relatively O
hihg O
frequency O
in O
an O
African O
Amaeicrn O
population O
( O
f O
= O
= O
0 O
. O
. O
09 O
, O
n O
61 O
subjects O
) O
 
The O
ARAS O
enzyme O
acityitv O
in O
subjects O
with O
and O
and O
whtuoit O
the O
R496H O
mutation O
was O
determined O
ofund O
to O
be O
normal O
. O
 
It O
is O
is O
therefore O
coculnded O
that O
the O
the O
Rh964 O
mttiuaon O
of O
of O
of O
ARSA O
RASA O
ARSA O
RASA O
does O
not O
not O
negatively O
influence O
activity O
and O
a O
uacse O
MLD B
 
Nowd O
- O
- O
regulation O
of O
transmembrane O
oarcbnic O
anhydrases O
in O
ernal B
renal B
llec I
cell I
inroaccma I
carcinoma I
cell O
lsnei O
by O
wild O
type O
von B
Hippel I
- I
Linadu I
Lindau I
transgenes O
. O
 
To O
drcsovei O
genes O
involved O
in O
von B
Eipphl I
Hippel I
- I
Lnaidu I
Lindau I
( O
VHL B
) O
- O
- O
- O
madieted O
acrgcnoienesis O
, O
we O
used O
neral B
renal B
lcle I
cell I
carcinoma I
cell O
lines O
stably O
transfected O
with O
wild O
type O
VHL O
expressing O
erantgsnes O
. O
 
Large O
- O
scale O
RNA O
differential O
disaply O
technology O
applied O
to O
these O
cell O
lenis O
identified O
several O
dfflerentialiy O
expressed O
genes O
, O
, O
including O
an O
alpha O
carbonic O
yndahrase O
gnee O
termed O
CA12 O
. O
 
The O
eeducdd O
rpetoin O
senqeuce O
was O
classified O
as O
a O
one O
- O
pass O
trmneaeabrmns O
CA O
CA O
possessing O
an O
apparently O
intact O
catalytic O
doniam O
in O
the O
extracellular O
module O
. O
 
Reintroduced O
liwd O
- O
tepy O
VHL B
strongly O
inhibited O
the O
the O
the O
overexpression O
of O
CA12 O
gene O
in O
perantal O
renal B
cell I
arcoinmac I
carcinoma I
cell O
ilnes O
. O
 
Similar O
results O
were O
obtained O
with O
with O
CA9 O
, O
encoding O
another O
trambmensrane O
CA O
an O
iantct O
cataltiyc O
domain O
. O
 
Although O
both O
domains O
of O
of O
the O
the O
VHL B
itorepn O
contribute O
to O
rtgulaoien O
CA21 O
expression O
expression O
, O
elongin O
binding O
daiomn O
alone O
could O
effectilevy O
regulate O
CA9 O
. O
 
We O
mapped O
CA12 O
and O
and O
CA9 O
olci O
to O
ohromcsmoe O
bands O
15q22 O
172q1 O
. O
 
2 O
respectively O
, O
rgeisno O
nrope O
to O
amplification O
in O
some O
human O
cersacn B
cancers B
. O
 
Additainol O
enxiremepts O
are O
eedden O
to O
difnee O
the O
the O
the O
orle O
of O
of O
CA O
CA O
IX O
and O
and O
XII O
emzyens O
in O
in O
regtoauiln O
pH O
extracellular O
microenvironment O
its O
potential O
impact O
on O
enccar B
cancer B
cell O
growth O
. O
 
A O
nege O
encoding O
a O
transmembrane O
piotren O
is O
tutamed O
in O
patients O
with O
diabetes B
lumestli I
mellitus I
and O
ptioc B
optic B
aophtry I
atrophy I
( O
Wolfram B
syndrome I
) O
. O
 
Wolfram B
syndrome I
( O
WFS B
; O
IMOM O
220320 O
) O
is O
an O
tomasauol B
autosomal B
recessive I
eanridnreouegteve I
neurodegenerative I
disorder I
defined O
by O
young O
- O
- O
osnet O
non O
immune O
lnusini B
insulin B
- I
nteeddenp I
dependent I
diabetes I
silmelut I
mellitus I
and O
progressive O
itopc B
optic B
rhpyato I
atrophy I
. O
 
Linkage O
to O
markers O
on O
mhrocosome O
4p O
was O
confirmed O
in O
fevi O
flmiiaes O
. O
 
On O
the O
the O
basis O
of O
of O
ieimtoc O
necombsnatri O
and O
disease O
- O
essociatad O
haplotypes O
, O
WFS B
gene O
was O
loacziled O
to O
a O
BAC O
/ O
P1 O
contig O
less O
than O
250 O
kb O
. O
 
Mutainots O
in O
in O
in O
a O
a O
onvel O
gene O
( O
WFS1 O
) O
encoding O
piattuve O
trarsemnbname O
protein O
were O
were O
found O
all O
acfeetfd O
individuals O
six O
WFS B
families O
, O
and O
these O
mutations O
associated O
with O
the O
disease O
ohpnptyee O
. O
 
FWS1 O
appears O
to O
iuncfton O
in O
survival O
of O
islet O
beta O
- O
sellc O
and O
neurons O
. O
. O
 
Stable O
inttrcaoien O
between O
the O
the O
orpudcts O
of O
BRCA1 O
and O
and O
BRCA2 O
tmuor B
tumor B
suppressor O
gnees O
in O
mitotic O
micotie O
cells O
. O
 
B1CAr O
and O
and O
BRAC2 O
account O
for O
most O
cases O
of O
familial O
, O
larey O
tnseo O
tasreb B
breast B
and I
/ I
or I
ivoraan I
ovarian I
enccar I
cancer I
encode O
products O
that O
each O
interact O
with O
hRAD51 O
. O
 
Rtselus O
tresenped O
here O
show O
that O
RBCA1 O
and O
and O
and O
BRCA2 O
coexist O
in O
in O
in O
a O
biochemical O
cmpolex O
colocalize O
subnuclear O
foci O
somatic O
cells O
on O
the O
axial O
leemsnte O
of O
doveleginp O
synaptonemal O
complexes O
. O
 
Like O
BRCA1 O
and O
ARD51 O
, O
CRBA2 O
relocates O
to O
to O
PCNA O
+ O
erpcilatoin O
sites O
following O
erpsouxe O
of O
S O
phase O
clles O
hydroxyurea O
or O
UV O
irradiation O
. O
 
Thsu O
, O
, O
, O
BRCA1 O
and O
and O
BRCA2 O
participate O
tgoeehtr O
in O
a O
pathway O
( O
s O
) O
associated O
with O
the O
aitcvatnoi O
of O
double O
- O
strand O
break O
eaprir O
/ O
or O
homologous O
micorbetanion O
. O
 
Dcsnnuytiof O
of O
of O
of O
this O
pathway O
may O
be O
a O
enegral O
phenomenon O
in O
the O
tajmrioy O
cases O
hdiaterery B
hereditary B
terabs I
breast I
and I
/ I
or I
anoaivr I
ovarian I
cenacr I
cancer I
. O
. O
 
A O
novel O
Arg362Ser O
muiattno O
in O
the O
sterol O
27 O
- O
- O
ohdrysylaxe O
gene O
( O
2YPc7 O
) O
: O
its O
effects O
on O
pre O
mRNA O
splicing O
and O
enzyme O
activity O
. O
 
A O
A O
novel O
C O
to O
auomtitn O
in O
the O
sterol O
27 O
- O
xydrhyolase O
gnee O
gene O
gnee O
gene O
( O
( O
7YP2c O
YCP27 O
7YP2c O
YCP27 O
) O
) O
was O
identified O
by O
sequencing O
amplified O
products O
from O
a O
patient O
with O
eerbeuotcnisnord B
cerebrotendinous B
oihtmanatosxs I
xanthomatosis I
CTX B
. O
 
The O
mutation O
changed O
the O
the O
adrenodoxin O
cofactor O
bndiing O
residue O
362Arg O
26gAr3 O
362Arg O
26gAr3 O
to O
to O
362Ser O
s6r3e2 O
362Ser O
s6r3e2 O
( O
CGT O
AGT O
) O
, O
, O
and O
was O
responsible O
for O
deficiency O
in O
sterol O
27 O
- O
- O
hyordxyslae O
activity O
as O
confirmed O
by O
expression O
of O
umnatt O
cDNA O
into O
COS O
1 O
clles O
. O
 
Quantitative O
analysis O
showed O
that O
the O
the O
expression O
of O
CYP27 O
gnee O
aRNM O
in O
pattine O
represented O
52 O
. O
 
5 O
% O
of O
the O
normal O
lelev O
. O
 
As O
the O
the O
the O
the O
the O
the O
mutation O
atumtion O
mutation O
atumtion O
rccuored O
at O
ptniutlmaee O
nucleotide O
of O
of O
of O
exon O
exon O
exon O
6 O
6 O
6 O
6 O
( O
- O
- O
2 O
pisiootn O
intron O
spilec O
stie O
) O
nege O
, O
, O
we O
hypothesized O
that O
may O
pyrtiaall O
affect O
normal O
splicing O
snlicgpi O
splicing O
snlicgpi O
efficiency O
in O
in O
in O
and O
cause O
alternative O
elweshree O
which O
resulted O
decreased O
transcript O
patient O
. O
 
Transfection O
of O
of O
constructed O
miengenis O
, O
, O
with O
or O
without O
the O
the O
the O
mutation O
into O
COS O
- O
1 O
cells O
comeirnfd O
that O
mutant O
einmgine O
was O
pesroislbne O
for O
a O
mRNA O
spceies O
alternatively O
spliced O
at O
an O
actavdtei O
cryptic O
5 O
siplce O
stie O
88 O
bp O
arstpeum O
from O
3 O
end O
exon O
6 O
. O
 
Our O
adta O
sugtesg O
that O
the O
the O
the O
the O
the O
C O
to O
to O
A O
tmtauion O
at O
penultimate O
nucleotide O
of O
of O
of O
exno O
6 O
CYP27 O
egne O
gene O
egne O
gene O
not O
only O
causes O
dcfecnyeii B
deficiency B
in I
the I
loestr I
sterol I
27 I
- I
dxhyorlyase I
hydroxylase I
ctvityai I
activity I
, O
but O
slao O
airtaplly O
leads O
alternative O
pre O
- O
mNRA O
splicing O
. O
 
To O
our O
kdowgenle O
, O
this O
is O
the O
the O
fsrit O
report O
raierdgng O
tcfefes O
on O
pre O
- O
- O
mRNA O
plsicing O
of O
of O
a O
a O
mutation O
at O
2 O
position O
5 O
splice O
stie O
. O
 
ATM O
gmrelnie O
nutatmois O
in O
in O
classical O
iaaxat B
ataxia B
- I
tenesgitcaalia I
telangiectasia I
patients O
the O
Dutch O
population O
. O
 
Ilrmegne O
mutations O
in O
the O
the O
ATM O
gene O
are O
rsnloseibpe O
for O
toaasumol B
autosomal B
rceesseiv I
recessive I
ridrsoed I
disorder I
taxiaa B
ataxia B
- I
- I
ieealginsaatct I
telangiectasia I
( O
A B
T I
) O
. O
 
In O
our O
study O
, O
, O
, O
we O
have O
determined O
the O
ATM O
mutation O
spectrum O
in O
19 O
classical O
A B
- I
T I
eatipnts O
incdulnig O
some O
gmaiirmnt O
aotulppions O
as O
as O
well O
12 O
of O
Dutch O
hetnic O
origin O
. O
 
Btoh O
the O
the O
the O
protein O
truncation O
test O
( O
( O
PTT O
) O
) O
and O
and O
and O
restriction O
endonuclease O
fingerprinting O
REF O
meohdt O
were O
used O
compared O
for O
their O
detoctein O
efficiency O
, O
, O
idnytnfeiig O
76 O
% O
% O
60 O
of O
matutoins O
rescelpivety O
. O
 
Most O
patients O
were O
fuond O
to O
be O
compound O
oteeyozrghte O
. O
 
Seventeen O
mutations O
were O
were O
dtsnitci O
, O
of O
which O
10 O
not O
depertor O
preoiuvsly O
. O
 
Mutations O
are O
slalm O
deletions O
or O
noipt O
mutations O
frequently O
affecting O
splice O
siets O
. O
 
Roveorem O
, O
a O
16 O
. O
 
7 O
- O
kb O
genomic O
deletion O
of O
of O
of O
the O
the O
3 O
end O
nege O
, O
, O
most O
llkiey O
a O
rtusle O
reonmbinaitco O
between O
two O
LNIE O
elements O
was O
identified O
. O
 
The O
most O
frequently O
found O
muiatton O
mutation O
muiatton O
mutation O
, O
, O
identified O
in O
ehrte O
unrelated O
Turkish O
Turkish O
A B
A B
- I
- I
T I
T I
diinliduavs O
was O
psevioruly O
described O
to O
be O
a O
founder O
. O
 
The O
presence O
of O
a O
a O
founder O
mutation O
anomg O
teearivlly O
small O
hcenit O
popolatiun O
groups O
in O
in O
Srwteen O
Europe O
could O
indicate O
high O
carrier O
frequency O
such O
communities O
. O
 
In O
pattines O
of O
Dutch O
etcinh O
origin O
, O
, O
however O
no O
significant O
founder O
effect O
uocld O
be O
identified O
. O
 
The O
observed O
genetic O
renehoietegty O
incnugild O
the O
the O
ielatvre O
high O
parctneege O
of O
splice O
- O
site O
mutations O
had O
no O
reflection O
on O
phenotype O
. O
 
All O
patients O
minaeestfd O
aacssicll O
A B
- I
T I
and O
increased O
cellular O
radioresistant O
DNA O
synthesis O
. O
 
Determination O
of O
of O
of O
the O
the O
genomic O
structure O
COL4A4 O
gene O
and O
novel O
ustationm O
uacsnig O
autosomal B
csvreisee I
recessive I
Otpalr I
Alport I
syndrome I
. O
 
Ouoasatlm B
Autosomal B
recessive I
Olptar I
Alport I
syndrome I
is O
a O
progressive O
hematuric B
glomiihronstepulre I
glomerulonephritis I
chtraczerdaei O
by O
glomerular B
basement I
enmmreba I
membrane I
taeorialmibns I
abnormalities I
and O
and O
associated O
with O
umtaitons O
in O
either O
the O
the O
the O
3LO4Ac O
or O
4OLac4 O
gene O
, O
, O
which O
encode O
paahl3 O
alpha4 O
type O
IV O
collagen O
hcsina O
respectively O
. O
 
To O
date O
, O
mutation O
snrcenieg O
in O
the O
the O
two O
gnees O
has O
been O
rhmpeaed O
by O
lack O
of O
genomic O
strurtuce O
information O
. O
 
We O
etporr O
here O
the O
the O
the O
the O
complete O
characterization O
of O
of O
of O
48 O
eoxns O
OCL44a O
gene O
gene O
, O
, O
a O
evmerchpnsioe O
screen O
and O
sebsuuqent O
detection O
10 O
novel O
mttnuioas O
in O
eight O
patients O
eiognasdd O
with O
sootamaul B
autosomal B
recessive I
Alport I
msedoryn I
syndrome I
. O
 
Frmthruroee O
, O
, O
we O
identified O
a O
glycine O
to O
aianlne O
substitution O
in O
in O
in O
the O
the O
collagunose O
domain O
that O
is O
apparently O
enlsit O
heterozygous O
iarrcres O
11 O
. O
 
5 O
% O
of O
all O
conlort O
ooltrcn O
conlort O
ooltrcn O
individuals O
, O
and O
in O
one O
individual O
homozygous O
for O
this O
lgicyne O
substitution O
. O
 
Htere O
has O
been O
no O
previous O
nindifg O
of O
a O
glycine O
sibntuiuttos O
that O
is O
not O
associated O
with O
any O
bouiovs O
hpentoype O
in O
homozygous O
individuals O
. O
 
Founder O
BR1Ac O
and O
BRCA2 O
mutations O
in O
French O
Acnadian O
etbsar B
breast B
and I
ovarian I
ncecar I
cancer I
families O
. O
 
We O
have O
identified O
four O
mtustiona O
in O
in O
each O
of O
the O
abesrt B
breast B
artbes B
abesrt B
breast B
artbes B
abesrt B
breast B
artbes B
ccaren I
cancer I
ccaren I
cancer I
ccaren I
cancer I
- O
sibteptisulicy O
geens O
, O
, O
BRCA1 O
and O
and O
ARCB2 O
French O
Canadian O
/ I
orviaan I
ovarian I
families O
from O
Qeubec O
. O
 
To O
identify O
founder O
effects O
, O
we O
enaximed O
independently O
ascertained O
French O
Canadian O
crncea B
cancer B
families O
for O
the O
distribution O
of O
these O
ieght O
mutations O
. O
 
Mutations O
were O
fnuod O
in O
41 O
of O
97 O
famleiis O
. O
 
Six O
of O
eight O
outamitns O
were O
observed O
at O
elast O
twice O
. O
 
The O
BRCA1 O
C4446T O
motauitn O
umoatitn O
mutation O
motauitn O
umoatitn O
mutation O
motauitn O
umoatitn O
mutation O
was O
the O
the O
most O
oomcmn O
found O
, O
leflowod O
by O
BRCA2 O
8765delAG O
. O
 
Together O
, O
these O
mtnatious O
were O
found O
in O
28 O
of O
41 O
afmiiles O
idenfitied O
to O
have O
a O
mutation O
. O
 
The O
odsd O
of O
of O
of O
detection O
any O
the O
four O
BCRA1 O
umnatiots O
was O
18 O
. O
 
7x O
greater O
if O
one O
or O
more O
cases O
of O
raivaon B
ovarian B
cancer I
were O
aslo O
prtesne O
in O
the O
mifaly O
. O
 
The O
dods O
of O
of O
of O
detceiton O
any O
the O
four O
BRCA2 O
otuatimns O
was O
5 O
. O
 
3x O
greetar O
if O
there O
were O
at O
least O
fvie O
saces O
of O
tsbare B
breast B
cancer I
in O
the O
family O
. O
 
Tnetresignily O
, O
the O
the O
the O
pcesrnee O
nersepce O
pcesrnee O
nersepce O
of O
of O
of O
of O
of O
a O
rbseat B
breast B
cancer I
csae O
< O
36 O
years O
age O
was O
srtongyl O
predictive O
any O
eight O
mutations O
screened O
. O
 
Earrisrc O
of O
the O
the O
the O
same O
outmtian O
mutation O
outmtian O
mutation O
, O
, O
, O
from O
different O
fseilima O
shared O
similar O
haplotypes O
indicating O
that O
mutant O
alleles O
were O
likely O
to O
be O
edintacil O
by O
descent O
for O
a O
in O
founder O
poputaoiln O
. O
 
The O
itentificaondi O
of O
common O
BRCA1 O
and O
and O
BRCA2 O
mutations O
will O
facilitate O
carrier O
tndectioe O
in O
French O
Iancdaan O
srteba B
saebrt B
breast B
srteba B
saebrt B
breast B
cancer I
cancer I
/ I
nvoriaa I
ovarian I
fimlaies O
. O
 
Are O
Dp71 O
and O
Dp104 O
irabn O
dystrophin O
isoforms O
related O
to O
gcoetnivi B
cognitive B
iptiarmnem I
impairment I
in O
Duchenne B
lcrsumau I
muscular I
dystrophy I
? O
 
Omlrculae O
utsdy O
and O
neuropsychological O
aansylis O
were O
performed O
concurrently O
on O
49 O
pttienas O
satieptn O
pttienas O
satieptn O
with O
Undhncee B
Duchenne B
cumruals I
muscular I
sdyhropyt I
dystrophy I
( O
DMD B
DMD B
) O
in O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B
mpiaitmenr I
impairment I
observed O
most O
. O
 
Complete O
analysis O
of O
of O
the O
the O
the O
hystrpodin O
egne O
was O
preformed O
to O
to O
define O
localization O
dntelioes O
and O
duplications O
in O
rilatnoe O
different O
DMD B
promoters O
. O
 
Qualitative O
analysis O
of O
of O
the O
the O
Pd71 O
traiscrnpt O
and O
testing O
for O
specific O
first O
exon O
Dp140 O
were O
alos O
iadrcer O
out O
. O
 
Neuropsychological O
analysis O
aesdsses O
verbal O
verbal O
and O
and O
visuospatial O
gnticlieenle O
, O
, O
memory O
aernidg O
skills O
. O
 
Sompariocn O
of O
of O
molecular O
and O
and O
psychometric O
isndingf O
demonstrated O
that O
that O
deletions O
duplications O
were O
eocallzid O
in O
the O
the O
distal O
part O
gnee O
meesed O
to O
be O
preferentially O
ataocissed O
with O
cognitive B
tmapnrmeii I
impairment I
. O
 
Two O
altered O
Dp71 O
transcripts O
and O
two O
deleted O
Pd140 O
DNA O
sequences O
were O
fuond O
in O
four O
tateinps O
with O
sveere O
lcraereb B
cerebral B
dysfunction I
. O
 
These O
findings O
segugst O
that O
some O
some O
sequences O
lotacde O
in O
in O
in O
the O
the O
the O
the O
distal O
prat O
of O
geen O
and O
, O
, O
particular O
DMD B
DMD B
siosormf O
expressed O
brian O
may O
be O
related O
to O
evogitinc B
cognitive B
ipemnamrit I
impairment I
associated O
with O
. O
. O
 
I1307K O
APC O
and O
hHLM1 O
iutatnoms O
in O
a O
non O
- O
Jshiew O
family O
with O
eerharidty B
hereditary B
non I
- I
plosysoip I
polyposis I
erlootclac I
colorectal I
cancer I
. O
 
We O
descbrie O
a O
a O
French O
Canadian O
heaeydtrri B
hereditary B
non I
- I
silpoosyp I
polyposis I
coelrlocat I
colorectal I
cancer I
( O
NHCCP B
HNPCC B
) O
nekdrid O
which O
carries O
eovnl O
truncating O
mutation O
in O
hMLH1 O
. O
 
Interestingly O
, O
, O
, O
the O
I1307K O
APC O
pilymsrphomo O
associated O
with O
an O
increased O
risk O
of O
rclaotceol B
colorectal B
cancer I
is O
aosl O
present O
in O
this O
mfaily O
. O
 
The O
I1307K O
polymorphism O
has O
pveriuosly O
only O
been O
identified O
in O
dnuiiivdals O
of O
self O
- O
reported O
Ashkenazi O
Jihesw O
nrisiog O
. O
 
In O
addition O
, O
, O
in O
this O
falmiy O
there O
appears O
to O
be O
no O
henitiolsrap O
between O
the O
the O
I1307K O
polymorphism O
and O
rpesence O
or O
acsenbe O
of O
nccaer B
cancer B
. O
. O
 
Identification O
of O
of O
a O
a O
novel O
mtatuion O
the O
CPO O
gene O
in O
Eapasenj O
hrrieatedy B
hereditary B
coproporphyria I
lamyfi O
. O
 
Hereditary B
ropporihyoprca I
coproporphyria I
( O
( O
HCP B
) O
) O
is O
an O
autosomal B
minoandt I
dominant I
disease I
chciaaetrrzed O
by O
by O
a O
a O
difyceince B
deficiency B
of I
orprcregpyooinophn I
coproporphyrinogen I
sxoaide I
oxidase I
CPO O
CPO O
esuacd O
mutation O
in O
the O
nege O
. O
 
Lnoy O
11 O
stuationm O
of O
the O
gene O
have O
been O
reported O
in O
HCP B
pasitnet O
. O
 
We O
report O
aonehtr O
mutation O
in O
a O
Japanese O
family O
. O
 
Polymerase O
chain O
eraciton O
- O
single O
rastnd O
conformational O
polymorphism O
and O
direct O
sncueeqe O
elanysas O
demonstrated O
a O
C O
to O
to O
T O
substitution O
in O
in O
exon O
1 O
of O
the O
the O
CPO O
eeng O
at O
nucleotide O
position O
85 O
, O
which O
lies O
patutive O
presequence O
for O
attgering O
miticrhndooa O
. O
 
This O
mutation O
shcngea O
the O
docon O
codon O
docon O
codon O
for O
glutamine O
to O
a O
termination O
at O
amino O
icad O
poiotsin O
29 O
. O
 
MaeI O
cestriotirn O
snilyaas O
showed O
two O
other O
carriers O
in O
the O
family O
. O
 
The O
C O
- O
- O
- O
- O
T O
mutation O
is O
is O
toacled O
within O
a O
recently O
proposed O
putative O
alternative O
tratsnlaion O
intiiation O
ocdon O
( O
TIC O
TIC O
TIC O
TIC O
1 O
1 O
) O
, O
pusportnig O
that O
the O
real O
rthaer O
than O
2 O
. O
. O
 
Human B
cmopnemlet I
complement I
orftca I
factor I
H I
deficiency I
aseociastd O
with O
ielhmtoyc B
hemolytic B
uremic I
onmdryse I
syndrome I
. O
 
Htis O
study O
reports O
on O
six O
csaes O
of O
of O
yeficdncei B
deficiency B
in I
the I
human I
tompenlemc I
complement I
gtoulaerry I
regulatory I
tpeorin I
protein I
Factor I
H I
( O
FH O
) O
in O
the O
onctext O
an O
acute B
aerln I
renal I
siedeas I
disease I
. O
 
Ifve O
of O
the O
cases O
were O
observed O
in O
erildhcn O
presenting O
with O
ihipoatdic O
hyeoimtlc B
hemolytic B
creium I
uremic I
syndrome I
( O
HUS B
) O
. O
 
Two O
of O
of O
of O
of O
the O
the O
the O
the O
the O
children O
exhibited O
a O
hoomgyzous O
denicfeicy O
characterized O
by O
basence O
150 O
- O
- O
- O
- O
- O
kD O
kD O
rofm O
Factor O
Factor O
H O
H O
and O
and O
persnece O
, O
, O
opun O
immunoblotting O
42 O
kile O
protein O
pretoni O
protein O
pretoni O
1 O
1 O
( O
( O
FHL O
) O
) O
other O
FH O
ereatld O
FHR O
bands O
. O
 
Rhutoesn O
blot O
and O
PCR O
naslyais O
of O
of O
of O
of O
DNA O
one O
patient O
with O
homozygous O
deficiency O
deficeicny O
deficiency O
deficeicny O
ruled O
out O
the O
the O
the O
the O
presence O
a O
ralge O
eedltion O
FH O
gene O
as O
nudelrying O
tcfeed O
for O
. O
 
The O
other O
rouf O
children O
presented O
with O
heterozygous O
deficiency O
and O
exhibited O
a O
anrmol O
immunoblotting O
pattern O
of O
of O
tporeins O
the O
FH O
faimyl O
. O
 
Cfaotr B
Factor B
H I
deficiency I
dfcieinecy I
deficiency I
dfcieinecy I
is O
the O
only O
oclpmement B
complement B
acdosiates O
with O
HUS B
. O
 
Thsee O
observations O
sguegst O
a O
role O
for O
FH O
FH O
and O
/ O
or O
eecrptors O
in O
the O
pathoiegnses O
of O
idiopathic O
HUS B
. O
. O
 
Ufrhter O
evidence O
for O
a O
major O
aecnnit O
mutation O
underlying O
myotonic B
hsytodrpy I
dystrophy I
from O
linkage O
disequilibrium O
studies O
in O
the O
Japanese O
popuiatoln O
. O
 
The O
imootync B
myotonic B
dystohpyr I
dystrophy I
( O
( O
DM B
DM B
) O
) O
mutation O
is O
an O
unstable O
CTG O
n O
rpeaet O
, O
present O
at O
a O
ocpy O
ubmner O
of O
5 O
- O
- O
37 O
repeats O
on O
on O
normal O
scromohomes O
chromosomes O
scromohomes O
chromosomes O
but O
amplified O
to O
50 O
3000 O
pscieo O
. O
 
Previous O
inidfngs O
in O
in O
Caucasian O
poplnaoitus O
of O
a O
a O
DM B
fdueonr O
chromosome O
raise O
euistqon O
about O
the O
the O
molecular O
events O
involved O
xpeansion O
mutation O
. O
 
To O
investigate O
heetwhr O
a O
noefdur O
ohrceosomm O
for O
the O
the O
the O
DM B
mutation O
exists O
in O
Japanese O
population O
, O
we O
geyotepnd O
femiails O
using O
polymorphic O
markers O
enar O
( O
CTG O
) O
n O
repeat O
region O
and O
constructed O
haplotypes O
. O
 
Six O
fefdirent O
haplotypes O
were O
were O
found O
and O
DM B
alllese O
always O
hapeptyol O
A O
. O
 
To O
dinf O
an O
origin O
of O
of O
the O
the O
the O
the O
( O
CTG O
) O
n O
repeat O
mutation O
tumatoin O
mutation O
tumatoin O
and O
and O
to O
investigate O
mechanism O
expansion O
in O
Japanese O
Japanese O
popoaltiun O
we O
have O
sdtuied O
90 O
DM B
famiiels O
cgmprisino O
190 O
eaffcted O
130 O
cnafftueed O
members O
. O
 
The O
results O
ueggsst O
that O
a O
few O
common O
ancestral O
ascrnteal O
ancestral O
ascrnteal O
tutaoimns O
in O
both O
Caucasian O
and O
Japanese O
populations O
have O
arigtnoied O
by O
epxonsian O
of O
an O
n O
n O
= O
= O
5 O
repeat O
to O
19 O
- O
37 O
cseipo O
. O
 
These O
aatd O
prpsout O
multistep O
doemls O
of O
terplit O
repeat O
expansion O
that O
have O
been O
proposed O
for O
both O
DM B
and O
Frcedrehiis B
Friedreichs B
ataaix I
ataxia I
. O
. O
 
The O
molecular O
basis O
of O
C6 B
deeccifiyn I
deficiency I
in O
the O
wsteern O
Cape O
, O
Stuoh O
Africa O
. O
 
Cefiecindy B
Deficiency B
of I
of I
the I
ihstx I
sixth I
component I
munha I
human I
comtelemnp I
complement I
( O
C6 O
) O
has O
been O
reported O
in O
a O
nubmre O
of O
families O
from O
the O
western O
Pace O
, O
South O
Rfaaci O
. O
 
Gloennoccmcia B
Meningococcal B
disease I
is O
denemic O
in O
the O
Cape O
and O
aomslt O
all O
pegidseer O
of O
of O
total O
C6 B
dcefcieniy I
deficiency I
( O
C6Q0 O
) O
have O
been O
ascertained O
because O
recurrnet O
disease O
. O
 
We O
have O
have O
have O
sequenced O
the O
the O
the O
the O
expressed O
enoxs O
of O
C6 O
gene O
from O
seeedtlc O
cases O
and O
and O
and O
and O
uofnd O
terhe O
molecular O
defects O
landieg O
to O
total O
deficiency O
879delG O
, O
, O
, O
which O
which O
is O
common O
defect O
in O
in O
Pace O
hitherto O
unreported O
19l5de1C O
d9316elG O
been O
previusoly O
reported O
African O
- O
Americans O
. O
 
We O
laso O
show O
that O
the O
8d79elG O
and O
1195delC O
defetcs O
are O
associated O
with O
characteristic O
C6 O
/ O
C7 O
region O
DNA O
marker O
haplotypes O
, O
although O
small O
raaivtions O
were O
bdserveo O
. O
 
The O
1936delG O
tfeecd O
was O
oebervsd O
only O
once O
in O
the O
Pace O
, O
but O
its O
associated O
taploeyph O
could O
be O
deduced O
. O
 
The O
data O
from O
from O
the O
the O
the O
the O
hleaotypps O
indicate O
that O
these O
trhee O
molecular O
defects O
defects O
nccouta O
for O
in O
all O
38 O
dnraleteu O
06Qc O
undilvdiais O
we O
have O
studied O
Cape O
. O
 
We O
have O
also O
observed O
the O
the O
the O
879delG O
987delG O
879delG O
987delG O
dcfeet O
defect O
dcfeet O
defect O
in O
in O
two O
Dutch O
C6 B
- I
ntdiciefe I
deficient I
kindreds O
, O
but O
Cape O
rlobabpy O
did O
not O
cmoe O
from O
The O
Rehtenlands O
. O
. O
 
Cnompeemlt B
Complement B
C7 I
difecyicen I
deficiency I
: O
eevsn O
further O
molecular O
defects O
and O
their O
associated O
raekmr O
haplotypes O
. O
 
Snvee O
further O
molecular O
bases O
of O
C7 B
ieficdncey I
deficiency I
are O
desercbid O
. O
 
All O
these O
new O
mollcreau O
dtcefes O
involve O
sinegl O
- O
nucleotide O
events O
, O
, O
, O
deletions O
and O
and O
busitntutioss O
some O
of O
which O
alter O
splice O
setis O
others O
codons O
. O
 
They O
are O
tisrtdbuied O
alnog O
the O
the O
C7 O
gene O
, O
but O
predominantly O
trdaows O
3 O
end O
. O
 
All O
were O
fnuod O
in O
compound O
heterozygous O
idaiuinvdls O
. O
 
The O
C6 O
/ O
C7 O
kamrer O
haplotypes O
associated O
with O
most O
C7 B
detecfs I
defects I
are O
taulbated O
. O
. O
 
A O
megone O
- O
wide O
search O
for O
for O
ahmorolomcs O
loci O
linked O
to O
mental O
health O
wellness O
in O
relatives O
at O
high O
irsk O
olirpab B
bipolar B
ctffeavie I
affective I
disorder I
among O
the O
Old O
Odrer O
Smiah O
. O
 
Lboaipr B
Bipolar B
affective I
siroddre I
disorder I
( O
BPAD B
; O
manic B
- I
deesvsrpei I
depressive I
elisnls I
illness I
) O
is O
rtrcacheaized O
by O
eipsoeds O
of O
of O
aiamn B
mania B
and O
/ O
or O
anhapmyio B
hypomania B
dnseitperser O
with O
periods O
depression B
. O
 
Compelling O
evidence O
supports O
a O
significant O
genetic O
cmoponent O
in O
the O
upicestibilsty O
to O
eeodlvp O
ABPD B
BPAD B
. O
 
To O
daet O
, O
, O
however O
linkage O
itsdues O
have O
attempted O
only O
to O
identify O
chromosomal O
loic O
that O
cause O
or O
nircease O
the O
risk O
of O
developing O
PABD B
BPAD B
. O
 
To O
determine O
hhwteer O
there O
cluod O
be O
protective O
alleles O
that O
prevent O
or O
reduce O
the O
the O
rsik O
of O
of O
of O
of O
developing O
BPAD B
BPAD B
, O
, O
similar O
to O
what O
is O
osrebved O
in O
in O
other O
gcetine B
genetic B
disorders I
we O
sued O
mental O
health O
wellness O
( O
absence O
any O
pciihystarc B
psychiatric B
diserrod I
disorder I
) O
as O
phenotype O
our O
gnoeme O
- O
wdie O
linkage O
scan O
several O
lgrae O
multigeneration O
Old O
Order O
Amish O
pedegrsei O
exhibiting O
an O
extremely O
hgih O
incidence O
. O
 
We O
have O
noufd O
strong O
cvidenee O
evidence O
cvidenee O
evidence O
for O
for O
a O
a O
locus O
locus O
on O
on O
mmrohosoce O
chormmsooe O
mmrohosoce O
chormmsooe O
4p O
at O
at O
D4S2949 O
( O
( O
( O
( O
( O
maximum O
maximum O
GENEHUNTER O
GENEHUNTER O
- O
- O
- O
- O
- O
LPUS O
PLUS O
LPUS O
PLUS O
prnnaocmetria O
nonparametric O
prnnaocmetria O
nonparametric O
aknilge O
linkage O
aknilge O
linkage O
score O
score O
= O
= O
= O
= O
4 O
4 O
. O
. O
. O
. O
05 O
, O
, O
P O
P O
5 O
5 O
22 O
x O
x O
x O
10 O
10 O
10 O
) O
) O
) O
; O
SBIAPL O
Pempirical O
lavue O
< O
3 O
3 O
3 O
and O
suggestive O
4q O
4dS937 O
29 O
2 O
57 O
 
) O
) O
) O
; O
SIBPAL O
Ermpipical O
ualve O
< O
1 O
x O
10 O
( O
- O
3 O
that O
are O
linked O
to O
malten O
health O
wellness O
. O
 
Shete O
findings O
are O
consistent O
with O
the O
the O
hypothesis O
that O
certain O
aelells O
uocld O
vperent O
or O
modify O
clinical O
taniaestfoimns O
of O
ABPD B
BPAD B
and O
perhaps O
other O
related O
affective B
rrosideds I
disorders I
. O
 
Sgergeation O
distortion O
in O
tyomcnio B
myotonic B
dystrophy I
. O
 
Mynocoti B
Myotonic B
ypstdhory I
dystrophy I
( O
DM B
) O
is O
an O
sutoaomal B
autosomal B
dominant I
disease I
which O
, O
, O
in O
the O
typical O
peeigrde O
shows O
a O
three O
generotian O
ancittpaioin O
cascade O
. O
 
Ihts O
results O
in O
in O
iietrnflity B
infertility B
and O
itagnnceol B
congenital B
myotonic I
dhysryopt I
dystrophy I
( O
CDM B
) O
with O
the O
dispraeapance O
of O
DM B
that O
peregdie O
. O
 
The O
concept O
of O
of O
of O
segregation O
distortion O
, O
, O
where O
there O
is O
teerrfenpial O
transmission O
the O
the O
the O
the O
gaelrr O
alllee O
at O
DM B
DM B
locus O
has O
been O
put O
forward O
to O
explain O
paltiarly O
neiatannmce O
in O
poupltaion O
. O
 
In O
a O
sryveu O
of O
DM B
in O
Eornhtrn O
Riealnd O
, O
59 O
pedigrees O
were O
ascertained O
. O
 
Sbpshiis O
where O
the O
the O
the O
the O
status O
of O
of O
all O
members O
had O
been O
idfnteiied O
were O
exmainde O
to O
to O
determine O
tanrmsission O
DM B
epxnasion O
from O
cffetaed O
parents O
their O
offspring O
. O
 
Where O
the O
transmintitg O
aprnet O
was O
male O
, O
58 O
. O
 
3 O
% O
of O
of O
the O
the O
offspring O
were O
tffecaed O
, O
, O
and O
in O
caes O
a O
afmele O
transmitting O
eprant O
68 O
. O
 
7 O
% O
were O
afedctef O
. O
 
Dtsuies O
on O
meiotic O
drive O
in O
in O
DM B
DM B
have O
shown O
enceiasrd O
oranssimnits O
of O
the O
the O
larger O
allele O
at O
locus O
non O
- O
DM O
hetorezytegos O
for O
TCGn O
. O
 
This O
study O
provides O
further O
evidence O
that O
the O
DM B
expansion O
etnds O
to O
be O
transmitted O
preflreitanely O
. O
 
Siagnidos O
of O
atihhmrooceosms B
hemochromatosis B
. O
 
If O
untreated O
, O
, O
casohtroiehosmm B
hemochromatosis B
can O
cause O
esirous O
iesnlls O
and O
early B
edath I
death I
but O
the O
dsseiae O
is O
still O
substantially O
under O
- O
diagnosed O
. O
 
The O
cornerstone O
of O
of O
screening O
and O
and O
case O
detection O
is O
the O
the O
measurement O
serum O
surem O
serum O
surem O
transferrin O
titurasaon O
retfirin O
eevll O
. O
 
Once O
the O
the O
diagnosis O
is O
suspected O
, O
physicians O
must O
use O
serum O
frriiten O
levels O
and O
hitapec O
iron O
stores O
on O
rivel O
sbopiy O
epscimsne O
to O
assess O
patients O
for O
presence O
of O
nori B
iron B
overload I
. O
 
Liver O
biopsy O
is O
also O
used O
to O
estsbailh O
the O
eeespncr O
or O
ansebce O
of O
isrciosrh B
cirrhosis B
, O
which O
can O
affect O
gronposis O
and O
management O
. O
 
A O
DNA O
- O
daseb O
etst O
for O
the O
the O
HFE O
gene O
is O
is O
commercially O
bvaialale O
, O
but O
its O
place O
in O
diagnosis O
of O
heossrtioahommc B
hemochromatosis B
still O
being O
aveeuatld O
. O
 
Curreytln O
, O
the O
the O
the O
the O
most O
sueful O
orle O
for O
this O
test O
is O
in O
in O
detection O
of O
of O
of O
riomstomoahches B
hemochromatosis B
mlfiay O
members O
patients O
with O
a O
rponev O
csae O
disease O
. O
 
It O
is O
crucial O
to O
to O
diagnose O
hemochromatosis B
before O
hpiaect B
hepatic B
irhsrcois I
cirrhosis I
dveoleps O
because O
phlebotomy O
therapy O
can O
can O
avert O
seirosu O
hcrinoc O
disease O
and O
enev O
lead O
normal O
life O
expyatcnce O
. O
. O
 
Pravelence O
of O
of O
the O
I1307K O
APC B
gene O
rivaant O
in O
Israeli O
Jews O
fidefring O
ethnic O
irgoin O
and O
risk O
for O
lcaerotcol B
colorectal B
ecnarc I
cancer I
. O
 
CABKORGUND O
& O
AIMS O
Israeli O
Iirsela O
Israeli O
Iirsela O
Jews O
of O
of O
Euaeporn O
ribth O
, O
, O
, O
i O
. O
. O
. O
e O
Ashkenazim O
have O
the O
highest O
colorectal B
cnrcae I
cancer I
incidence O
any O
ethnic O
group O
 
The O
I1307K O
APC B
gene O
iarvant O
was O
fodnu O
in O
6 O
. O
 
1 O
% O
% O
of O
of O
American O
Jwes O
Jews O
Jwes O
Jews O
, O
, O
28 O
their O
lamfiial O
olecractlo B
colorectal B
cancer I
casse O
but O
not O
in O
non O
- O
. O
 
We O
asssesde O
the O
I1307K O
prevalence O
in O
Israeli O
Jews O
of O
riifedfng O
ethnic O
oiinrg O
and O
risk O
for O
arocoelctl B
colorectal B
cancer I
. O
 
HETOMDS O
DNA O
samples O
from O
500 O
unrelated O
Ejws O
of O
of O
European O
Eeroupan O
European O
Eeroupan O
or O
or O
or O
non O
- O
- O
origin O
, O
, O
with O
without O
a O
nersolap O
and O
/ O
maifly O
tisyorh O
naaolpsie B
neoplasia B
were O
examined O
for O
the O
the O
I1307K O
variant O
by O
allele O
specific O
loigondclioteue O
( O
ASO O
) O
teohmd O
. O
 
RESULTS O
In O
pensros O
at O
aavrege O
risk O
for O
colorectal B
canecr I
cancer I
, O
I1307K O
was O
noufd O
in O
5 O
. O
 
0 O
% O
of O
120 O
Enroaepu O
and O
1 O
. O
 
6 O
% O
of O
188 O
non O
- O
Eurenoap O
Ejws O
( O
P O
= O
0 O
. O
. O
08 O
) O
 
It O
oecurrcd O
in O
15 O
. O
 
4 O
% O
of O
52 O
Ashkenazi O
Israelis O
with O
familial O
cancer B
cnrcea B
cancer B
cnrcea B
( O
P O
= O
0 O
. O
. O
02 O
) O
and O
was O
not O
deteetcd O
in O
51 O
non O
- O
Eunoepar O
Wejs O
at O
increased O
sirk O
 
Ltalrecooc B
Colorectal B
alpaensoi I
neoplasia I
occurred O
sernopally O
or O
or O
in O
the O
families O
of O
of O
of O
of O
13 O
20 O
Ashkenazi O
I1307K O
cirrasre O
, O
8 O
whom O
also O
had O
a O
personal O
limafy O
hstiory O
noniolcnoc O
neoplasia B
. O
 
CONCLUSIONS O
The O
I1307K O
APC O
iarvnat O
may O
rnpeesret O
a O
susceptibility O
gene O
for O
aotoreclcl B
octllercao B
colorectal B
aotoreclcl B
octllercao B
colorectal B
, I
, I
or I
other I
anrcces I
cancers I
in O
in O
Anhzesaki O
Jews O
, O
and O
aartillpy O
sxelainp O
the O
higher O
incidence O
of O
ccaner I
cancer I
European O
Israelis O
. O
 
Syitesatmc O
sanlyais O
of O
coproporphyrinogen O
oxidase O
geen O
defects O
in O
hereditary B
pochopprrryoia I
coproporphyria I
and O
mutation O
update O
. O
 
Hyrdtiaere B
Hereditary B
riphacprpoyroo I
coproporphyria I
( O
( O
HC B
) O
) O
is O
an O
acute O
hepatic B
rpyophair I
porphyria I
with O
outosaaml O
dominant O
inheritance O
euascd O
by O
tdeiicnfe B
deficient B
iytaticv I
activity I
of I
coproporphyrinogen I
III I
ioxasde I
oxidase I
CPO O
. O
 
Clinical O
manifestations O
of O
of O
the O
disease O
are O
ahercceariztd O
by O
by O
acute O
akatcts O
ucoiganorell B
neurological B
oycftuinsnd I
dysfunction I
ofetn O
precipitated O
dsugr O
, O
, O
, O
fasting O
cyclical O
hormonal O
changes O
or O
infectious B
diseases I
. O
 
Skin O
ptohosensiiivtty O
may O
aosl O
be O
present O
. O
 
The O
seven O
seven O
exons O
, O
, O
, O
the O
the O
exon O
exon O
exon O
/ O
intron O
eoundairbs O
and O
and O
part O
of O
of O
3 O
noncoding O
sequence O
CPO O
gnee O
were O
systematically O
analyzed O
by O
by O
by O
an O
- O
- O
dneatirung O
gradtine O
gel O
eoscirlphoreets O
( O
GGDE O
) O
strategy O
fldoowel O
direct O
sceuqneing O
in O
unrelated O
hgzerosyeout O
HC B
patients O
from O
France O
Holland O
Ccezh O
Republic O
. O
 
Seven O
novel O
motatinus O
and O
two O
new O
polmyohprsims O
were O
detected O
. O
 
Aomng O
these O
outitamns O
two O
two O
two O
are O
are O
are O
missense O
( O
( O
( O
( O
G197W O
, O
, O
, O
, O
, O
W427R O
) O
) O
) O
) O
nonsense O
Q360X O
Q358X O
smlal O
deletions O
662de14bp O
; O
1168del3bp O
reionmvg O
a O
a O
a O
glycine O
at O
position O
390 O
and O
one O
is O
splicing O
mutation O
VIS1 O
- O
- O
- O
15c O
> O
g O
which O
creates O
new O
acpector O
eplcis O
site O
. O
 
The O
pathological O
significance O
of O
the O
the O
iopnt O
mutations O
G197W O
, O
, O
W427R O
and O
in O
in O
- O
- O
frame O
oeletidn O
390delGly O
were O
aessessd O
by O
their O
rvspeetice O
expression O
a O
prokaryotic O
system O
isung O
site O
dietcerd O
mutagenesis O
. O
 
These O
mutitsona O
resulted O
in O
the O
absence O
or O
a O
dramatic O
decrease O
of O
CPO O
acttiviy O
. O
 
The O
two O
polymorphisms O
were O
iacollzed O
in O
in O
in O
noncoding O
ioncndong O
noncoding O
ioncndong O
rapt O
part O
rapt O
part O
of O
of O
of O
of O
the O
the O
the O
the O
the O
the O
the O
egne O
gene O
egne O
gene O
1 O
) O
) O
) O
) O
a O
a O
C O
/ O
/ O
G O
G O
polymorphism O
polymorphism O
oropotmr O
region O
, O
, O
, O
142 O
bp O
bp O
bp O
upmtsear O
from O
transcriptional O
initiation O
site O
( O
( O
- O
412C O
and O
2 O
6 O
deletion O
3 O
CPO O
574 O
574 O
downstream O
last O
sabe O
normal O
termination O
cdoon O
+ O
delCATTTT O
. O
 
Vife O
intriaengc O
rimdpohisms O
are O
now O
well O
raeracthcized O
and O
the O
high O
degree O
of O
of O
allelic O
hetetogeirney O
in O
HC B
is O
demonstrated O
with O
sveen O
new O
ditnereff O
mutations O
making O
a O
total O
nineteen O
CPO O
gnee B
gene B
setcfed I
defects I
reported O
so O
far O
. O
. O
 
Coiicednnce O
of O
of O
two O
novel O
arylsulfatase O
A O
A O
alleles O
and O
mutotian O
459 O
+ O
1G O
> O
within O
a O
afimly O
with O
metachromatic B
rluhydyskpteoo I
leukodystrophy I
: O
molecular O
bssia O
phenotypic O
heyeroeengitt O
. O
 
In O
a O
family O
with O
with O
three O
sinilbgs O
, O
, O
, O
one O
developed O
ccissalal O
late O
infantile O
mtimahcoacter B
metachromatic B
loekyoyptudshr I
leukodystrophy I
( O
( O
( O
MLD B
) O
) O
) O
fatal O
at O
age O
5 O
years O
deiicneft O
arylsulfatase O
A O
ARSA O
activity O
and O
rnciesaed O
yelactolglsusdatifa O
GS O
eocterixn O
. O
 
The O
two O
other O
iislsngb O
, O
, O
, O
, O
, O
apparently O
apparently O
healthy O
healthy O
at O
12 O
( O
1 O
/ O
2 O
) O
and O
and O
and O
15 O
years O
eesepctivrly O
their O
afhter O
as O
lewl O
prdseeten O
ARSA O
GS O
vlaeus O
within O
the O
range O
of O
MLD B
aptients O
. O
 
Auimtton O
ecrennisg O
and O
sequence O
analysis O
disclosed O
the O
the O
involvement O
of O
of O
three O
different O
ARSA O
mutations O
being O
loaecumlr O
sabis O
intrafamilial O
phenotypic O
heierogeentty O
. O
 
The O
leta O
infantile O
piatent O
inherited O
from O
from O
his O
his O
mother O
the O
frequent O
0 O
- O
type O
mutation O
459 O
+ O
1G O
> O
A O
, O
, O
and O
father O
a O
loven O
silgen O
basepair O
microdeletion O
of O
guaneni O
at O
nocleuitde O
7 O
in O
exon O
1 O
( O
gdel7 O
) O
. O
 
The O
two O
clinically O
unaffected O
siblings O
creaird O
the O
matlanre O
mutation O
459 O
+ O
1G O
> O
A O
and O
, O
, O
, O
on O
their O
lapernat O
aeelll O
a O
novel O
cytosine O
to O
thymidine O
transition O
at O
nucleotide O
2435 O
in O
in O
oxen O
8 O
tesurling O
sobtsitutiun O
of O
alanine O
464 O
by O
nlaive O
( O
A464V O
) O
. O
 
The O
fathers O
genotype O
tuhs O
was O
lde7G O
/ O
A464V O
. O
 
Mutation O
A464V O
was O
not O
ofund O
in O
18 O
unrelated O
MLD B
taniepts O
and O
50 O
otnorcls O
. O
 
A464V O
, O
, O
, O
although O
rlelcay O
mofidginy O
ARSA O
ARSA O
and O
GS O
levels O
arpatenply O
bears O
little O
significance O
for O
claincil O
manifestation O
of O
MLD B
mimicking O
the O
nerqueft O
pseudodeficiency O
allele O
. O
 
Our O
results O
odmensttare O
that O
in O
certain O
genetic O
conditions O
MLD B
- O
kile O
RASA O
and O
and O
GS O
seluav O
need O
not O
be O
larapleled O
by O
clinical O
disease O
, O
a O
finding O
with O
iorseus O
diagnostic O
prognostic O
implications O
. O
 
Moreoevr O
, O
, O
, O
, O
further O
ARSA O
SRAA O
ARSA O
SRAA O
lsleael O
fuacoilnntly O
similar O
to O
A464V O
might O
xeist O
which O
together O
with O
0 O
- O
type O
mutations O
may O
cuase O
pathological O
and O
GS O
levels O
but O
not O
clinical O
outbreak O
of O
the O
disease O
. O
. O
 
Hmuan O
LMH1 O
deficiency O
predisposes O
to O
metgoaolaihcl B
hematological B
nlaimncgay I
malignancy I
and O
siiroeafronutobsm B
neurofibromatosis B
type I
1 I
. O
 
Heterozygous O
germ O
- O
nile O
mutations O
in O
the O
DNA O
mismatch O
rapeir O
genes O
laed O
to O
derieathry B
hereditary B
nonpolyposis I
loocaecrlt I
colorectal I
cancer I
. O
 
The O
disease O
sucsyptilibite O
of O
individuals O
who O
clostnoutiniatly O
lack O
both O
wild O
- O
type O
lelelas O
is O
unknown O
. O
 
We O
have O
identified O
ehrte O
ofpsfirng O
in O
a O
a O
hereditary B
pinloynsopos I
nonpolyposis I
oallrcetoc I
colorectal I
enccar I
cancer I
aimfly O
who O
developed O
ogaaelohlcimt B
hematological B
malignancy I
at O
at O
very O
raely O
age O
, O
and O
least O
two O
of O
of O
them O
displayed O
nigss O
neurofibromatosis B
ptye I
type I
1 I
( O
NF1 B
) O
. O
 
DNA O
sequence O
analysis O
and O
llelae O
- O
- O
- O
cpseific O
amplification O
in O
two O
siblings O
revealed O
a O
homozygous O
MHL1 O
mutation O
( O
C676T O
> O
22gra6Stop O
) O
. O
 
Thus O
, O
a O
a O
ohyozmgous O
germ O
- O
ilne O
MLH1 O
mutation O
and O
and O
consequent O
sitmamch O
ieaprr O
deficiency O
results O
in O
umtarot O
phenotype O
characterized O
by O
iemeukla B
leukemia B
/ O
or O
lymphoma B
associated O
with O
nsoesfrbatmorioiu B
neurofibromatosis B
ypte I
type I
1 I
. O
. O
 
Missense O
mutations O
in O
the O
the O
most O
ancient O
rseieuds O
of O
of O
XAP6 O
praied O
doamni O
underlie O
a O
spectrum O
human O
enagcoinlt B
congenital B
eye I
aoslrmmofiant I
malformations I
. O
 
Mutations O
of O
the O
human O
XAP6 O
egne O
underlie O
iinrdaia B
aniridia B
( O
logaecntin B
congenital B
eneascb I
absence I
of I
of I
the I
the I
iirs I
iris I
) O
, O
a O
rare O
dominant O
molfmnritoaa B
malformation B
eye I
. O
 
The O
spectrum O
of O
of O
of O
of O
APX6 O
mutations O
iutatmnos O
mutations O
iutatmnos O
in O
adriinia B
aniridia B
patetnis O
is O
hilygh O
siadeb O
, O
, O
, O
with O
92 O
% O
% O
all O
reprtoed O
leading O
leading O
to O
to O
premature O
troncutian O
the O
protein O
( O
( O
nonsense O
splicing O
insertions O
and O
and O
deletions O
) O
) O
just O
2 O
substitution O
one O
aimno O
acid O
by O
naoehtr O
missense O
. O
 
The O
extraordinary O
conservation O
of O
the O
the O
PAX6 O
protein O
at O
amino O
caid O
level O
amongst O
revaebtrtes O
predicts O
that O
pactologahil O
sinmesse O
mutations O
should O
in O
in O
fact O
be O
common O
even O
though O
they O
are O
hladry O
ever O
esen O
diiraian B
aniridia B
patients O
. O
 
This O
indicates O
that O
that O
there O
is O
a O
haevy O
rsietaacnment O
bias O
in O
the O
the O
selection O
of O
patients O
for O
PAX6 O
PAX6 O
mutation O
analysis O
and O
msisnig O
mesnisse O
mutations O
fnuqeertly O
may O
inuerlde O
phenotypes O
discittn O
from O
textbook O
naiairdi B
aniridia B
. O
 
Hree O
we O
present O
four O
novel O
P6Xa O
mesnessi O
moiattuns O
, O
, O
two O
two O
in O
in O
ascasiitoon O
association O
ascasiitoon O
association O
with O
with O
atypical O
phenotypes O
phenotypes O
etcpiao B
ectopia B
piplueal I
pupillae I
( O
( O
displaced B
upipsl I
pupils I
) O
) O
and O
and O
cngnetialo B
congenital B
nystagmus I
searching B
gaze I
more O
recognizable O
adianiir B
aniridia B
. O
 
Strikingly O
, O
all O
all O
four O
mutations O
are O
are O
located O
witihn O
the O
PXA6 O
padier O
paired O
padier O
paired O
domain O
domain O
and O
feafct O
amino O
acids O
which O
highly O
conserved O
in O
knnwo O
proteins O
. O
 
Our O
results O
uspport O
the O
the O
hspothesiy O
that O
that O
under O
- O
representation O
of O
of O
essiensm O
mutations O
is O
daesuc O
by O
ascertainment O
bias O
and O
suggest O
a O
substantial O
edrubn O
PAX6 B
- I
leadret I
related I
disasee I
disease I
rnmiaes O
to O
be O
uncovered O
. O
. O
 
The O
chromosomal O
order O
of O
genes O
controlling O
the O
major O
ilttcoompasibhiity O
clopmex O
, O
, O
properdin O
factor O
B O
and O
fcdyeienci B
deficiency B
of I
of I
the I
ocnsed I
second I
tpconomne I
component I
cneplmmoet I
complement I
. O
 
The O
relationship O
of O
of O
the O
geens O
coding O
coding O
for O
for O
for O
HLA O
to O
those O
porpdrein O
Factor O
B O
aollpytes O
and O
ynfceicedi B
deficiency B
of I
of I
the I
socend I
second I
oenpocmnt I
component I
coepnemmlt I
complement I
( O
C2 O
) O
was O
dtisued O
in O
families O
aptinets O
with O
toncecnive O
tissue O
disorders O
. O
 
Patients O
were O
were O
sectleed O
because O
they O
heterozygous O
or O
homoyzgous O
for O
C2 B
eecniidyfc I
deficiency I
. O
 
12 O
falisiem O
with O
15 O
magtnis O
informative O
for O
C2 B
ceniicdefy I
deficiency I
were O
found O
. O
 
Of O
57 O
rntoimfaive O
moisees O
, O
, O
two O
crossovers O
were O
noted O
between O
the O
the O
C2 B
feedicincy I
deficiency I
geen O
gene O
geen O
gene O
and O
HLA O
- O
B O
with O
a O
ranombinetc O
froaticn O
of O
0 O
. O
 
035 O
. O
 
A O
lod O
score O
of O
of O
of O
13 O
was O
calculated O
for O
likeagn O
between O
C2 B
deciincefy I
deficiency I
and O
HLA O
- O
B O
at O
a O
xamimum O
hiielklood O
value O
the O
tenomnicabr O
fracotin O
0 O
. O
 
04 O
. O
 
18 O
fiimlaes O
with O
21 O
informative O
mtainsg O
for O
both O
properdin O
Aftcor O
B O
B O
ollytape O
and O
HLA O
- O
were O
found O
. O
 
Of O
72 O
informative O
meioses O
, O
, O
three O
rceombsnanti O
were O
found O
giving O
a O
retomnianbc O
fioctran O
of O
0 O
. O
 
042 O
. O
 
A O
lod O
socre O
of O
of O
of O
16 O
between O
HLA O
- O
B O
B O
and O
Factor O
allotypes O
was O
calculated O
at O
a O
umxiamm O
likelihood O
vulae O
the O
reocmbinant O
fraction O
0 O
. O
 
04 O
. O
 
A O
A O
ososrcver O
was O
hsown O
to O
have O
rceurocd O
between O
genes O
for O
Oacftr O
B O
B O
and O
and O
HLA O
HLA O
HLA O
- O
- O
- O
D O
D O
, O
in O
which O
segaeerrgd O
with O
. O
 
These O
studies O
suggest O
that O
that O
that O
that O
that O
the O
the O
the O
the O
the O
the O
geens O
genes O
geens O
genes O
geens O
genes O
for O
for O
for O
Factor O
Afcrot O
Fatcro O
Factor O
Afcrot O
Fatcro O
Factor O
Afcrot O
Fatcro O
Factor O
Afcrot O
Fatcro O
B O
B O
B O
B O
B O
B O
and O
and O
and O
and O
and O
C2 B
C2 B
C2 B
C2 B
deneycfici I
difceiecny I
icecidefny I
iedycfenci I
deficiency I
deneycfici I
difceiecny I
icecidefny I
iedycfenci I
deficiency I
deneycfici I
difceiecny I
icecidefny I
iedycfenci I
deficiency I
deneycfici I
difceiecny I
icecidefny I
iedycfenci I
deficiency I
are O
are O
doctael O
outside O
those O
HLA O
HLA O
HLA O
HLA O
, O
, O
, O
, O
, O
, O
, O
order O
of O
of O
genese O
is O
- O
- O
- O
- O
- O
- O
- O
A O
A O
D O
allotype O
ondicg O
allotypes O
atyroximapelp O
3 O
5 O
centimorgans O
from O
loci O
appraent O
lcak O
recombinants O
between O
gene O
gene O
suggests O
these O
two O
lie O
in O
lcose O
proximity O
to O
one O
ahotenr O
. O
 
Totsribudiin O
of O
eenrim O
and O
and O
lamins O
in O
the O
heart O
capliimoitns O
for O
Ermye B
Emery B
- I
Ussiedrf I
Dreifuss I
usmaclur I
muscular I
dystrophy I
. O
 
Emerin O
is O
is O
a O
encluar O
membrane O
protein O
which O
mnsiisg O
or O
defvitcee O
in O
Emery B
- I
Dreifuss I
mslucuar I
muscular I
dystrophy I
( O
DMED B
EDMD B
) O
. O
 
It O
is O
one O
mmebre O
of O
of O
a O
family O
lamina O
- O
stsociaaed O
proteins O
which O
includes O
LAP1 O
, O
LAP2 O
and O
laimn O
B O
eecrtpor O
( O
LBR O
) O
. O
 
A O
panel O
of O
16 O
monoclonal O
antobidsei O
( O
mAbs O
) O
has O
has O
been O
been O
mapped O
to O
to O
six O
specific O
sites O
htroughout O
the O
emiren O
rmeein O
emiren O
rmeein O
lloecume O
suing O
phage O
- O
displayed O
peptide O
libraries O
and O
and O
usde O
localize O
in O
human O
rabbit O
heart O
. O
 
Several O
mAbs O
against O
dfifenert O
emerin O
opipetes O
did O
not O
rezogeicn O
intercalated O
discs O
in O
in O
the O
the O
heart O
, O
, O
gtouhh O
they O
recognized O
cdrcaomyoiyte O
nuclei O
strongly O
both O
at O
rim O
and O
intranuclear O
spots O
or O
channels O
. O
 
A O
pocynlolal O
babtir O
antuesrim O
against O
against O
emerin O
mieren O
emerin O
mieren O
did O
rcnogeize O
both O
nuclear O
nuclear O
membrane O
membrane O
and O
intercalated O
discs O
but O
, O
, O
after O
affinity O
purification O
a O
a O
pure O
- O
band O
on O
tsewern O
blot O
it O
staeind O
only O
the O
. O
 
These O
reutlss O
louwd O
not O
be O
expected O
if O
immunostaining O
at O
iaetrcnlaetd O
inlaecrtated O
iaetrcnlaetd O
inlaecrtated O
dcsis O
discs O
dcsis O
discs O
were O
due O
to O
a O
product O
of O
of O
the O
the O
emerin O
emerin O
egne O
and O
, O
, O
oherefert O
cast O
some O
doubt O
upon O
phyothesis O
that O
cidrcaa B
cardiac B
defects I
in O
DDME B
EDMD B
are O
caused O
by O
absence O
from O
. O
 
Hltgouah O
emerin O
was O
was O
abundant O
in O
in O
the O
the O
bnmmraees O
of O
ycrdiymoocate O
nuclei O
, O
it O
absent O
from O
amny O
non O
- O
myocyte O
sellc O
heart O
. O
 
This O
distribution O
of O
of O
of O
emerin O
was O
similar O
to O
that O
liman O
A O
, O
a O
candiadte O
gnee O
for O
an O
autosomal O
rofm O
EMDD B
EDMD B
. O
 
In O
contrast O
, O
, O
laimn O
lamin O
laimn O
lamin O
B1 O
B1 O
was O
asebnt O
from O
cardiomyocyte O
nuclei O
whgsino O
that O
is O
not O
essential O
for O
lozlticaaion O
of O
emerin O
to O
the O
nuclear O
lamina O
. O
 
Lamin O
B1 O
is O
also O
msaolt O
completely O
absent O
from O
steleakl O
cusmel O
nuclei O
. O
 
In O
MEDD B
EDMD B
, O
the O
additional O
absence O
of O
of O
lamin O
B1 O
from O
reaht O
and O
llesetak O
muscle O
nuclei O
which O
already O
alck O
emerin O
may O
fofer O
an O
aieernatlvt O
explanation O
why O
these O
tissues O
are O
pyrtiluaarcl O
affected O
. O
. O
 
Genetic O
apmping O
of O
the O
copper B
iooctxsis I
toxicosis I
lucos O
in O
in O
Eodlingtbn O
terriers O
to O
to O
dog O
chrmoomose O
chromosome O
chrmoomose O
chromosome O
10 O
, O
a O
region O
greion O
region O
greion O
syntenic O
human O
2p13 O
- O
p16 O
. O
 
Abamronl O
hatpiec B
hepatic B
copper I
aucoalutmcin I
accumulation I
is O
iegocnrzed O
as O
an O
inherited B
irsdroed I
disorder I
in O
man O
, O
, O
omuse O
rat O
and O
dog O
. O
 
The O
amjor O
cause O
of O
chtepia B
hepatic B
copper I
lacniomctauu I
accumulation I
in O
man O
is O
a O
dlsfnucyionat O
PTA7B O
gene O
, O
causing O
Lowsni B
Wilson B
disease I
( O
WD B
) O
. O
 
Motauitns O
in O
in O
the O
ATP7B O
genes O
have O
also O
been O
damdnstrteeo O
msuoe O
and O
rat O
. O
 
The O
ATP7B O
gene O
has O
been O
excluded O
in O
the O
much O
rarer O
human O
eporcp B
copper B
ovldeora I
overload I
saseide O
non B
- I
Idiann I
Indian I
childhood I
orirschis I
cirrhosis I
, O
indicating O
gieetnc O
eetnrogheeity O
. O
 
By O
investigating O
the O
common O
muaosotal O
recessive O
epprco B
copper B
oitscosix I
toxicosis I
( O
CT B
) O
in O
in O
Bedlington O
trerreis O
, O
we O
have O
identified O
a O
new O
locus O
ievvlond O
prsroesgive O
reivl B
liver B
disease I
. O
 
We O
mxaeined O
wtheher O
the O
the O
WD B
egne O
A7PtB O
TAP7B O
A7PtB O
TAP7B O
was O
also O
causative O
for O
CT B
by O
investigating O
chromosomal O
co O
- O
localization O
of O
and O
C04107 O
, O
usgni O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
. O
 
C04107 O
is O
an O
aoonnmyus O
microsatellite O
marker O
sloecly O
linked O
to O
CT B
. O
 
However O
, O
, O
, O
BAC O
lsonec O
containing O
TAP7B O
and O
and O
C74001 O
mapped O
to O
to O
the O
nnaice O
chromosome O
regions O
CFA22q11 O
CFA10q26 O
respectively O
demonstrating O
that O
WD B
ocnnat O
be O
homologous O
CT B
. O
 
The O
copper O
orrnsptat O
gesen O
genes O
gesen O
genes O
CTR1 O
and O
CRT2 O
were O
also O
excluded O
as O
candidate O
for O
CT B
since O
they O
both O
pamped O
to O
canine O
chromoeoms O
region O
CFA11q22 O
. O
 
2 O
- O
22 O
. O
 
5 O
. O
 
A O
transcribed O
eequsnce O
identified O
from O
from O
the O
40c107 O
- O
- O
contniiang O
BAC O
was O
fonud O
to O
to O
be O
homologous O
a O
a O
gene O
expressed O
hmuan O
chromosome O
231p O
p16 O
, O
region O
devoid O
of O
any O
poailionst O
candidate O
genes O
. O
 
Molecular O
anaiysls O
of O
of O
the O
the O
APC B
APC B
gene O
in O
in O
in O
205 O
families O
: O
extended O
ptnoeyge O
- O
phenotype O
corlrnatioes O
FAP B
and O
evidence O
for O
role O
amino O
acid O
nhacegs O
tolcreoacl B
colorectal B
cecanr I
cancer I
piedrpsosition O
. O
 
BACKGROUND O
/ O
AIMS O
The O
dovmpeleent O
of O
of O
of O
of O
colorectal B
cancer I
and O
a O
vareabil O
range O
extracolonic O
manifestations O
in O
limafial B
familial B
asaomnoetud I
adenomatous I
loipoysps I
siloppyso I
polyposis I
loipoysps I
siloppyso I
polyposis I
( O
( O
FAP B
) O
) O
is O
the O
the O
seurlt O
dominant O
inheritcnae O
aesnomoaudt B
adenomatous B
coli I
APC B
egne O
mutations O
. O
 
In O
this O
stduy O
, O
eidrct O
mutation O
nsalyais O
of O
of O
the O
the O
APC B
APC B
gene O
was O
performed O
to O
to O
determine O
genotype O
- O
- O
pyepothne O
correlations O
for O
neni O
extracolonic O
manifestations O
and O
investigate O
incidecne O
mutations O
in O
non O
FAP O
coleaotcrl B
colorectal B
anrcec I
cancer I
. O
 
METHODS O
The O
APC B
nege O
was O
analysed O
in O
190 O
unrelated O
FAP B
and O
and O
15 O
non O
- O
FAP O
erccolotal B
colorectal B
caecnr I
cancer I
iatpents O
using O
denaturing O
eradigtn O
gel O
electrophoresis O
, O
, O
the O
protein O
tnurcation O
test O
direct O
siqneuceng O
. O
 
RSELUTS O
Chain O
terminating O
nsgials O
were O
only O
identified O
in O
itapents O
patients O
itapents O
patients O
belonging O
to O
the O
FAP B
group O
( O
105 O
) O
. O
 
Amino O
acid O
changes O
were O
identified O
in O
four O
aptneits O
patients O
aptneits O
patients O
, O
rhtee O
of O
of O
whom O
eebongld O
to O
the O
non O
- O
FAP O
guorp O
calorolcet B
colorectal B
cancer I
. O
 
Genotype O
- O
phenotype O
correlations O
identified O
significant O
differences O
in O
in O
the O
nature O
of O
ceritan O
oxtareolcnic O
manifestations O
FAP B
pniteats O
belonging O
to O
ehrte O
mutation O
subgroups O
. O
 
CONCOUSNLIS O
Extended O
negptyoe O
- O
phenotype O
corrisatnoel O
maed O
in O
this O
study O
may O
have O
the O
the O
poteaitnl O
to O
determine O
most O
apertproaip O
surveillance O
and O
prophylactic O
treatment O
regemins O
for O
those O
patients O
with O
with O
mutations O
associated O
life O
threatening O
conditions O
. O
 
This O
stduy O
olsa O
provided O
evidence O
for O
the O
pathological O
nartue O
of O
amino O
caid O
changes O
in O
APC O
associated O
with O
both O
FAP B
and O
non O
- O
FAP O
tlrcoecola B
colorectal B
raccne I
cancer I
patients O
. O
. O
 
Inherited B
colorectal I
yolppisso I
polyposis I
and O
cnerac B
cancer B
sirk O
of O
the O
APC O
I7310K O
polymorphism O
. O
 
Germ O
- O
line O
and O
and O
somatic O
trunticang O
mutations O
of O
the O
APC B
gene O
are O
thought O
to O
initiate O
colrtoclae B
colorectal B
tumor I
fmriatoon O
in O
lfmialai B
familial B
adsmneuaoto I
adenomatous I
soliyppos I
polyposis I
syndrome I
sdoripac O
colorectal O
caicinsgensore O
, O
respectively O
. O
 
Rectleny O
, O
an O
isoleucine O
- O
- O
- O
> O
eynisl O
polymorphism O
at O
codon O
1307 O
( O
0137iK O
) O
of O
of O
the O
the O
APC B
gene O
has O
been O
idefeinitd O
in O
6 O
% O
% O
7 O
Hsanekazi O
Jewish O
population O
. O
 
To O
assess O
the O
the O
risk O
of O
of O
this O
common O
APC B
allelic O
nraiavt O
in O
crloceotal O
sgrcinoneaesic O
, O
we O
have O
znaleayd O
a O
lrage O
corhot O
unselected O
Ashkenazi O
Jewish O
subjects O
with O
ooednumtaas B
adenomatous B
ylopps I
polyps I
and O
. O
. O
or O
ltlcoecoar B
colorectal B
cancer I
, I
for O
APC O
I1307K O
holimosppyrm O
 
The O
APC O
I170k3 O
allele O
was O
inedtifide O
in O
48 O
( O
10 O
. O
. O
1 O
% O
) O
of O
476 O
pttianes O
 
Compared O
with O
with O
the O
the O
frequency O
in O
two O
pesareta O
poiulapton O
control O
groups O
, O
APC O
1k307I O
allele O
is O
asseciaotd O
an O
estimated O
relative O
rsik O
of O
1 O
. O
 
5 O
- O
1 O
. O
 
7 O
for O
colorectal B
loeinpasa I
neoplasia I
( O
both O
P O
= O
. O
. O
01 O
) O
 
Furmrehrote O
, O
, O
, O
compared O
with O
nocsaerirrn O
APC O
I1307K O
crrsiear O
had O
inerdasce O
numbers O
of O
admneoas B
adenomas B
and O
etlrocaocl B
colorectal B
cancers I
per O
patient O
( O
P O
= O
. O
. O
03 O
) O
as O
as O
well O
a O
noyuger O
age O
at O
diagnosis O
 
We O
conclude O
that O
the O
APC O
I1307K O
tariavn O
deals O
to O
to O
increased O
ademnoa B
adenoma B
formation O
and O
ditlcrey O
cuntrobties O
3 O
% O
% O
- O
4 O
of O
all O
Ashkenazi O
Jehiws O
aeloorcclt B
colorectal B
cancer I
. O
 
The O
estimated O
revalite O
risk O
for O
for O
carriers O
may O
may O
tusijfy O
sficipec O
clinical O
screening O
the O
the O
360 O
, O
, O
000 O
Americans O
expdceet O
to O
harbor O
this O
this O
allele O
and O
tenegic O
tnstgei O
in O
in O
setting O
of O
long O
- O
- O
term O
outcome O
studies O
impact O
significantly O
on O
colorectal B
narcec I
cancer I
prevention O
pioulatopn O
. O
 
Localization O
of O
hamun O
BRCA1 O
and O
its O
loss O
in O
gihh O
- O
grade O
, O
non B
- I
inhedetri I
inherited I
bretsa I
breast I
acsciomanr I
carcinomas I
. O
 
Ulthhago O
the O
the O
the O
lnik O
between O
BRCA1 O
RBCA1 O
BRCA1 O
RBCA1 O
uumotr B
tumour B
- O
sropuesspr O
gene O
and O
hereditary B
breast I
and I
oraiavn I
ovarian I
acecnr I
cancer I
is O
is O
established O
, O
, O
, O
role O
if O
any O
of O
in O
non B
- I
iilfaaml I
familial I
ceacrns I
cancers I
unclear O
. O
 
BRCA1 O
BRCA1 O
mutations O
are O
rrae O
in O
in O
opsiradc B
sporadic B
nrscaec I
ecnrcsa I
cancers I
nrscaec I
ecnrcsa I
cancers I
, O
but O
loss O
of O
resulting O
from O
rueecdd O
espoexsirn O
or O
incorrect O
subcellular O
lonalizaoitc O
is O
postulated O
to O
be O
inmortapt O
non B
- I
familial I
erbast I
breast I
and I
aranvoi I
ovarian I
. O
 
Epngeietic O
loss O
, O
, O
, O
, O
, O
, O
however O
has O
not O
ecerived O
geernal O
pccentaace O
due O
to O
to O
to O
to O
controversy O
regarding O
the O
the O
the O
scbrellluau O
localization O
of O
of O
BRCA1 O
proteins O
reports O
which O
have O
rengda O
from O
exclusively O
nuclear O
nuclear O
conditionally O
ER O
/ O
golgi O
mtyopsalcic O
invaginations O
into O
nuescul O
. O
 
In O
an O
etpamtt O
to O
resolve O
this O
issue O
, O
we O
have O
comprehensively O
characterized O
19 O
anti O
- O
RBCA1 O
anitbdoies O
. O
 
These O
reagents O
detect O
a O
220 O
- O
kD O
protein O
olcaeizld O
in O
in O
dscirete O
nuceral O
foci O
all O
epithelial O
cell O
lines O
, O
inulndicg O
those O
eedivrd O
from O
sbtare B
breast B
malignancies I
. O
 
Immunohismacheticol O
staining O
of O
human O
barest O
breast O
barest O
breast O
specimens O
also O
reeavled O
BRCA1 O
nuclear O
foci O
in O
benign O
, O
vnvsaiie B
invasive B
laulrob I
lobular I
cancers I
and O
low B
- I
adger I
grade I
ductal I
aarcinomcs I
carcinomas I
. O
 
Conversely O
, O
, O
, O
BRCA1 O
BCRA1 O
BRCA1 O
BCRA1 O
expression O
was O
ceduerd O
or O
undbtlctaeee O
in O
the O
the O
majyrtio O
of O
of O
of O
of O
gihh O
- O
grade O
duatcl B
ductal B
carcinomas I
suggesting O
that O
absence O
may O
contburite O
to O
pathogenesis O
a O
significant O
percentage O
sporadic B
rasbet I
breast I
crescan I
cancers I
. O
. O
 
